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Abstract 
 
Dementia is a complex terminal disease that involves cognitive and 
functional declines and behavioral/psychological symptoms. Currently >5 million 
Americans suffer from dementia. The societal economic burden of dementia 
consists of different types of costs (value of informal care, out-of-pocket 
expenditures, Medicaid long-term care expenditures, and Medicare 
expenditures), and several payers (family, Medicaid, and Medicare) shoulder 
different amounts of the economic responsibility. To facilitate comprehensive 
planning at the family, state, and federal levels, policymakers must understand 
who incurs dementia costs over the course of the disease. 
 The objective of this study was to estimate the lifetime and annual cost of 
dementia care (value of informal care, out-of-pocket expenditures, Medicaid long-
term care expenditures, and Medicare expenditures), and the extra cost of caring 
for someone with dementia compared to someone who did not exhibit dementia 
clinical features (net cost).  
To estimate total and net lifetime and annual costs we developed an 
evidence-based mathematical model to simulate disease progression for newly 
diagnosed individuals with dementia. Data driven trajectories of three clinical 
features -cognition, function, and behavioral/psychological symptoms- were used 
to model disease severity. Personal characteristics, clinical features, place of 
residence, and dual enrollment status were used to estimate cost. Counterfactual 
  iii 
analysis was conducted to compare costs between those who did and did not 
exhibit clinical features (net cost).  
From time of diagnosis (mean age of 83 years), discounted total cost of 
care for a person with dementia was $322,900. Families incurred 72% of the total 
cost burden ($144,160 for informal caregiving and $88,780 out-of-pocket 
payments). Medicaid accounted for 12% ($37,390) and Medicare accounted for 
16% ($52,540) of total cost, respectively. In counterfactual analysis, net 
cumulative costs for a person with dementia were $194,890 greater over a 
lifetime than someone without dementia (85% of net cost incurred by families). 
 Our model extends previous studies by considering costs over the life 
course of the disease. We found that dementia results in $194,890 additional 
total care costs over an individual’s lifetime. The extra cost associated with 
dementia is primarily borne by families (versus Medicare or Medicaid) due to time 
spent providing informal care and out-of-pocket expenditures. 
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Chapter 1: Specific Aims 
 
 2 
Dementia, a complex, neurodegenerative disease, affects more than 5 
million Americans.1 Persons with dementia experience progressive declines in 
cognitive and functional ability and a wide range of challenging 
behavioral/psychological symptoms resulting in the need for caregiving from 
families over time.2,3 The intense caregiving needs of the disease often result in 
individuals with dementia being placed in long-term care facilities.4,5 
Consequently, dementia is the single greatest cause of disease burden exacting 
a substantial health-related toll on individuals with dementia and their families, 
and disproportionately higher health and social service related costs.6 As the 
population ages over the next 25 years, there will be approximately 13 million 
dementia cases placing unprecedented economic burden on society.7,8 Thus, 
there is a need to derive an accurate accounting of dementia costs from which 
effective interventions and policies can be developed and to help plan for future 
Medicare, Medicaid, and individual out-of-pocket spending.9  
Previous attempts to monetize dementia care have involved two 
methodological approaches, regression and simulation, with each presenting 
significant limitations.10-13 Both approaches have typically relied on a single 
indicator of disease severity, most often cognitive impairment. Yet functional 
dependence and behavioral/psychological symptoms are equally important 
markers of disease severity, and ignoring these symptoms may lead to an 
underestimation of cost.10-12 Functional limitations and behavioral/psychological 
symptoms in particular are a significant driver of long-term care needs and 
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cost.14-16 Furthermore, most regression studies provide estimates of the cost 
burden at a single point although dementia and associated care costs unfold over 
time.  
To address these limitations and derive more accurate cost projections, 
we developed a data-driven microsimulation model that simulated a unique 
patient’s progressions over the course of the disease and accounted for patient-
specific characteristics (cognition, function, and behavioral/psychological 
symptoms) and their variation over time. Microsimulation methods more closely 
model the natural progression of dementia by relaxing the restrictive assumptions 
of traditional simulation models that assume a homogenous disease trajectory. 
Data from the National Alzheimer’s Coordinating Center Uniform Data Set were 
used to estimate longitudinal disease trajectories (cognition, function, and 
behavioral/psychological symptoms). We linked cross-sectional data from the 
nationally representative Aging, Demographics, and Memory Study to CMS 
Medicare data to estimate the association between cognition, function, and 
behavioral/psychological symptoms and direct (e.g., medical costs, long-term 
care expenditures, expenditures for formal caregiving for activities of daily living) 
and indirect (e.g., time providing informal care for daily assistance) cost. The 
model synthesized trajectory and cost functions to estimate individual 
expenditures over the life course of the disease. Our specific aims were to:  
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Aim 1. Evaluate how three clinical features of dementia (cognition, 
function, and behavioral/psychological symptoms) change over time following a 
dementia diagnosis (Chapter 3). 
Aim 2. Evaluate the independent contributions of three clinical features of 
dementia (cognition, function, and behavioral/psychological symptoms) to the 
direct (Chapter 4) and indirect (Chapter 5) costs of dementia. 
Aim 3. Evaluate the lifetime and annual cost of dementia care, and the 
extra cost of caring for someone with dementia compared to someone who did 
not exhibit dementia clinical features (net cost) by using a microsimulation 
approach that takes account of clinical trajectories (Chapter 6). 
 This study is novel in its application of a microsimulation approach to 
derive the lifetime cost of dementia.  Results can inform national policy and 
decision makers concerning how cognition, function, and 
behavioral/psychological symptoms impact costs over time by payer.  This study 
is responsive to the goals of the National Alzheimer’s Project Act and focuses on 
priority populations (the elderly) of the Agency for Healthcare Research and 
Quality.  
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Chapter 2: Significance and Background 
 
 6 
Dementia, a neurodegenerative and terminal disorder that involves 
cognitive and functional declines and behavioral/psychological symptoms, is one 
of the most costly diseases in the US.1,17,18 Over 5 million Americans suffer from 
dementia and more than 15 million people provide unpaid caregiving.1 As the 
population ages over the next 25 years, there will be approximately 13 million 
dementia cases placing significant financial strain on Medicare, Medicaid, and 
families.8,19 Accurately understanding the sources of costs and projecting costs 
over the life course of the disease will help in the development of effective 
interventions and financial planning.9 
In 2010, an estimated $215 billion was spent on dementia care.17 Costs, 
which vary by place of residence (e.g., the community), include both direct (i.e., 
medical costs paid by Medicare, out-of-pocket medical costs, long-term care 
expenditures, and paid caregiving for activities of daily living) and indirect (i.e., 
time value of informal caregiving for activities of daily living care).17,20 The high 
cost of dementia is due to the disproportionate use of healthcare and long-term 
care services and the need for caregiving (formal and informal).13,17,21 Long-term 
care and caregiving costs are incurred primarily by families and Medicaid.17,22-25  
Previous research provides estimates of total (i.e., cost among those with 
dementia) and net (cost difference between those with and without dementia) 
direct and indirect costs of dementia; however, these prior studies have important 
methodological limitations including the use of small homogeneous samples.13,26-
40 More importantly, most regression-based studies evaluate total cost based on 
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a single indicator of disease severity, primarily cognitive impairment.13 These 
studies do not provide a comprehensive understanding of the direct and indirect 
costs of dementia as they exclude the functional consequences and 
behavioral/psychological symptoms that are common and potentially the most 
costly aspects of the disease.41-45 Furthermore, functional ability and 
behavioral/psychological symptoms are better predictors of informal caregiving in 
dementia.15,29,32,46 Finally, most prior studies use cross-sectional data and are 
unable to account for the significant variability in symptoms and their timing. For 
example, although behavioral/psychological symptoms are almost universal, they 
can come and go across the disease trajectory.41 As disease trajectories vary, 
basing cost on cognitive status or one indicator of disease severity at one time 
point limits the accuracy of results, and does not provide policymakers with an 
avenue for evaluating interventions aimed at other dimensions of the disease.40,47 
This study overcomes previous limitations by modeling individual trajectories to 
infer cost over the course of the disease.  
The most generalizable estimates of the net cost of dementia were 
recently reported by researchers from RAND and the University of Michigan.17 
However, the RAND study did not evaluate how costs accumulate over the 
course of the disease nor did it analyze the contributions of dementia-related 
symptoms that trigger expenditures.17 We adapted the RAND methodology to 
evaluate the total and net costs of dementia. In contrast to the RAND study, we 
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evaluated the total and net lifetime cost of the disease and evaluate the relative 
contributions of dementia-related symptoms that trigger expenditures. 
Simulation-based studies (e.g., Markov models) have extended results 
from regression-based studies to provide a more detailed estimate of costs on a 
population level.10-12 However, modeling studies have been criticized for the use 
of cohort models that impose a standard disease trajectory and modeling disease 
progression based on cognitive status alone.12,48-53 Modeling disease trajectory 
through multiple domains (e.g., cognition, function, and behavior) is important 
because the domains of disease severity may differentially impact cost and 
treatments intervene through different pathways.10  
This study overcomes these limitations by using microsimulation methods, 
which relax the restrictive assumptions of traditional cohort models and explicitly 
take into account patient history and characteristics (e.g., cognition, function, and 
behavior) to inform cost over the life course of the disease. While these methods 
have been used to model complex health conditions such as cancer and 
depression, they have not been adequately applied to dementia.54-56 Model 
results can help inform decision makers about how costs accumulate over time 
and the payers responsible for cost. 
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Chapter 3: Cognitive, Functional, and Behavioral 
Trajectories  
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3.1 Overview   
 
BACKGROUND: Dementia results in changes in cognition, function, and 
behavioral/psychological symptoms. We examine the effect of sociodemographic 
and clinical risk factors on cognitive, functional, and behavioral/psychological 
declines in incident dementia patients. 
METHODS: We used longitudinal data from the National Alzheimer’s 
Coordinating Center to evaluate cognitive (Mini-Mental State Examination 
[MMSE]), functional (Functional Activities Questionnaire [FAQ]), and 
behavioral/psychological (Neuropsychiatric Inventory Questionnaire [NPI-Q] 
severity score) trajectories for incident dementia patients over an 8-year period. 
We evaluated trajectories of 457 patients with mixed-effects linear regression 
models. 
RESULTS: In the first year, cognition worsened by -1.518 (95% CI -1.745, -
1.291) MMSE points (0 – 30 scale). Education, race, and region of residence 
predicted cognition at diagnosis. Age of onset, geographic region of residence, 
and history of hypertension and congestive heart failure predicted cognitive 
changes. Function worsened by 3.464 (95% CI 3.131, 3.798) FAQ points in the 
first year (0 – 30 scale). Cognition, gender, race, region of residence and place of 
residence, and a history of stroke and hypercholesterolemia predicted function at 
diagnosis. Place of residence and a history of diabetes predicted functional 
changes. Behavioral/psychological symptoms worsened by 0.354 (95% CI 0.123, 
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0.585) NPI-Q points in the first year (0 – 36 scale). Age of onset, region of 
residence, and history of hypertension and psychiatric problems predicted 
behaviors at diagnosis. Cognition explained changes in behavior.  
CONCLUSIONS: Sociodemographic characteristics and clinical co-morbidities 
predict cognitive and functional changes. Only cognitive status explains 
behavioral/psychological decline. Results provide an understanding of the 
characteristics that impact cognitive, functional, and behavioral/psychological 
decline. 
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3.2 Introduction 
Dementia is a complex neurodegenerative disease that affects over five 
million Americans.57-59 The defining clinical features of dementia include 
progressive declines in cognitive and functional ability and a wide range of 
challenging behavioral/psychological symptoms that occur throughout the 
disease process.60,61 While all persons with dementia experience cognitive, 
functional, and behavioral/psychological changes, transitions over time are not 
uniform.41,60 Understanding which predictors accelerate or decelerate decline can 
help providers and families better prepare for caring of individuals with dementia. 
Unfortunately, the factors that impact changes in newly diagnosed dementia 
patients are poorly understood. 
 Previous studies evaluating cognitive, functional, and 
behavioral/psychological trajectories have significant limitations including limited 
patient follow up, combined incident and prevalent cases, failure to account for 
attrition, and evaluating functional decline and behavioral/psychological 
symptoms independent of cognitive status despite evidence of their 
interrelatedness.41,62-66 Furthermore, these prior studies focused primarily on 
biomedical predictors of decline (e.g., vascular risk factors) and largely ignored 
sociodemographic characteristics including race, marital status, geographical 
region, and place of residence.  Although these elements are risk factors for 
developing dementia, there is limited research concerning their impact on decline 
following a dementia diagnosis.57-59 
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Our study seeks to identify predictors of cognitive, functional, and 
behavioral/psychological declines in a diverse sample of newly diagnosed 
dementia patients. This study fills an important void in the literature by evaluating 
the role of dementia risk factors on decline after disease onset. We conducted an 
exploratory data analysis to evaluate the impact of sociodemographic and clinical 
risk factors on trajectories for cognition, function, and behavioral/psychological 
symptoms. Results may assist in care planning and help to focus future 
interventions on those factors that have the greatest effect on decline on these 
three areas. 
 
3.3 Methods 
3.3.1 Study Setting and Participants 
 We used data from the National Alzheimer’s Coordinating Center (NACC), 
which serves as a data hub for 34 past and present Alzheimer’s Disease Centers 
(ADCs).60 Patients are enrolled in ADCs by clinical referral, self-referral, and 
active ADC recruitment. Depending on the ADC, a single clinician or consensus 
panel make a dementia diagnosis. ADCs attempt to follow all patients annually 
using a standardized protocol that includes cognitive, functional, and behavioral 
assessments.  During annual assessments trained ADC clinicians and staff 
administer the data collection protocol in-person or over the phone to obtain data 
from patients and informants (e.g., spouse).  The NACC combines patient data 
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across ADCs in a publically available longitudinal file called the Uniform Data Set 
(UDS). 60  
 For this study, we used the UDS (March 2015 data freeze) and limited our 
analysis to newly diagnosed individuals >70 years old (i.e., incident dementia 
cases; Figure A3.1).41,62-66 Although the UDS provides diagnostic categories 
(e.g., Alzheimer’s dementia), we did not limit our analysis to a specific type of 
dementia because diagnosis is subject to a high degree of misclassification.67-69 
To evaluate disease progression over time within an individual and to account for 
non-linear change, we further limited our analysis to individuals with at least two 
observations post dementia diagnoses. Finally, we required individuals to have 
complete observations on variables of interest for their first observation.  
 
3.3.2 Measures of Dementia 
 The progression of dementia was assessed in terms of cognition, function, 
and behavioral/psychological symptoms as these are the defining clinical 
features of the disease.61 During annual ADC assessments cognitive status was 
measured using the Mini-Mental State Examination (MMSE).70 The MMSE was 
completed by clinicians and scored from 0 to 30 with lower scores indicating 
greater cognitive impairment.  Functional ability was assessed using the 
Functional Activities Questionnaire (FAQ). The FAQ was administered by 
clinicians to informants and was scored from 0 to 30 with higher scores indicating 
greater functional impairment.71 behavioral/psychological symptoms were 
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assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). The NPI-
Q was administered by clinicians to informants and was scored from 0 to 36 with 
higher scores indicating greater severity of behavioral symptoms.72 
  
3.3.3 Explanatory Variables 
Sociodemographic risk factors available in the UDS include age at time of 
diagnosis, gender, educational attainment, race, marital status, geographic 
region, and place of residence (community, facility). Clinical risk factors include 
self-reported history of hypertension, diabetes, congestive heart failure, stroke, 
hypercholesterolemia, or psychiatric problems. All covariates except place of 
residence in the previous observation and marital status were coded as time-
invariant. 
  
3.3.4 Statistical Analysis 
 We used separate linear-mixed effects models to evaluate cognitive, 
functional, and behavioral/psychological trajectories of incident dementia 
patients. We initially constructed simple models where time, measured as years 
since a diagnosis of dementia, was the only predictor of change. To evaluate 
non-linear trajectories and individual deviation from the population mean 
trajectory, we tested the inclusion of a squared term for time and random effects 
terms for both intercepts and slopes. Akaike information criterion was used as a 
measure of fit to determine the best fitting simple models. Based on our analysis 
 16 
of the simple models, all models included a term for time-squared and a random 
intercept and random slopes for both the linear and quadratic terms (Equation 
A3.2).  
We extended this preliminary model to estimate the association between 
dementia risk factors and cognitive, functional, and behavioral/psychological 
change.  Because previous models did not evaluate the effect of both 
sociodemographic and clinical factors on change and due to our a-priori interest 
in their associations, we included main effects (i.e., not interacted with time) for 
these predictors regardless of statistical significance.  In models evaluating 
functional and behavioral/psychological trajectories, cognitive status was also 
included as a time-varying main effect. The functional and 
behavioral/psychological models also controlled for informant type (e.g., spouse) 
as these measures are based on informant input.  We then used a model 
building approach (described below) to determine the inclusion of interactions 
between sociodemographic and clinical predictors with time (i.e., slope effects). 
We did not evaluate interactions with time-squared because preliminary analyses 
examining these interactions resulted in poor fit (e.g., wild fluxuations in the tails 
of predicted functional trajectories that are not representative of measurement 
error or normal variation). Poor model fit appeared to reflect sparse data over 
time for certain combinations of covariates. The model building process began 
with a model that included all predictors and the interaction of all predictors with 
time. Interactions with an alpha >0.10 were identified as potentially poor fitting 
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and candidates for exclusion. Using the likelihood ratio test we tested the 
reduced model (i.e., the model without the interaction) against the full model (i.e., 
the model with the interaction term). We retained the full model if the p-value of 
the likelihood ratio test was <0.05. This strategy allowed for non-significant 
interactions to remain in the model if their inclusion resulted in a better fitting 
model. To aid in the comparison of trajectories we also used the final models to 
estimate the effect of covariates on standardized cognitive, functional, and 
behavioral/psychological decline (i.e., where only the outcome variable is 
standardized by subtracting the mean value at baseline from an individual’s 
observed value and dividing by the baseline standard deviation). All analyses 
excluded individuals that requested not to participate in follow up assessments 
(i.e., dropouts; n = 96) as they had higher cognitive scores at time of diagnosis 
(Table A3.3).  In a sensitivity analysis, we included these individuals in our final 
models.  
Using the final models, we predicted the annual rate of change by year 
and trajectories over 8 years. All statistical analyses were conducted using Stata 
12.1 (College Station, Texas).  
 
3.4 Results 
3.4.1 Sample Characteristics 
 Of the 457 individuals who met the study inclusion criteria, the mean age 
of individuals in the analytic sample at time of diagnosis was 79 years, 55% were 
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male, and 8% were African American (Table 3.6.1). Due to few observations, 
American Indians, Alaskan Natives, Native Hawaiians, Asians, and individuals 
who identified as multiracial were grouped in the “other” racial category. 
   
3.4.2 Cognitive Trajectories 
 As noted above, all models contained main effects for sociodemographic 
and medical predictors. The best fitting cognitive model included additional terms 
for the interaction of age of onset, region of residence, hypertension, and 
congestive heart failure with time (Equation A3.4). Holding all variables in the 
fully adjusted model at their sample mean, the average rate of cognitive decline 
in the first year was -1.518 (95% CI: -1.745, -1.291) MMSE points (Table 3.6.2).  
As depicted in Figure 3.7.1 (Panel 1), the rate of cognitive decline accelerated 
over time.  
Results of the mixed effects model evaluating cognitive trajectories are 
reported in Table 3.6.3 (Table A3.5 reports standardized cognitive trajectories 
and results of the sensitivity analysis which included individuals that dropped 
out). In the table, negative coefficients indicate a predictor is associated with 
greater cognitive impairment. At time of diagnosis those with less education, 
African Americans compared to whites and individuals living in the West 
compared to the Northeast had lower cognitive scores. Older age of onset, 
residing in the Northeast compared to the West, and a history of hypertension 
and congestive heart failure were associated with slower decline. 
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3.4.3 Functional Trajectories 
The best fitting functional model included additional terms for the 
interaction of cognition, education, place of residence, and diabetes with time 
(Equation A3.6). Holding all variables in the fully adjusted model at their sample 
mean, the average rate of functional decline in the first year was 3.464 (95% CI: 
3.131, 3.798) FAQ points (Table 3.6.2). As depicted in Figure 3.7.1 (Panel 2), 
the rate of functional decline slowed over time.  
Results of the mixed effects model evaluating functional decline are 
presented in Table 3.6.4 (Table A3.7 reports standardized functional trajectories 
and results of the sensitivity analysis which included individuals that dropped 
out). In the table, positive coefficients indicate a predictor is associated with 
greater functional limitations. At time of diagnosis, higher cognitive status, males, 
African Americans compared to whites, residing in the Midwest compared to the 
Northeast, living in the community, and having a history of hypercholesterolemia 
were associated with fewer functional limitations. Place of residence and a 
history of diabetes had a significant effect on functional decline over time. 
  
3.4.4 Behavioral/Psychological Trajectories 
The best fitting behavioral/psychological model included additional terms 
for the interaction of cognition and stroke with time (Equation A3.8). Holding all 
variables in the fully adjusted model at their sample mean, the severity of 
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behavioral/psychological problems worsened by 0.354 (95% CI: 0.123, 0.585) 
NPI-Q points in the first year (Table 3.6.2). As depicted in Figure 3.7.1 (Panel 
3), the rate of behavioral/psychological decline accelerated over time.  
Results of the mixed effects model evaluating behavioral/psychological 
trajectories are presented in Table 3.6.5 (Table A3.9 reports standardized 
behavioral/psychological trajectories and results of the sensitivity analysis which 
included individuals that dropped out). In the table, positive coefficients indicate a 
predictor is associated with more severe behavioral/psychological problems. Age 
of dementia onset, residing in the South compared to the Northeast, and a 
history of hypertension and psychiatric problems were significant predictors of an 
individual’s behavioral score at time of diagnosis.  Only cognitive function had an 
effect on behavioral trajectories over time.  
 
3.5 Discussion 
Our objective was to examine rates of decline over 8 years for three 
defining clinical features of dementia (cognition, function, and 
behavioral/psychological symptoms) in newly diagnosed dementia patients. 
Previous studies have shown the effect of sociodemographic characteristics and 
medical history on the risk of developing dementia.58,59 However few studies 
have explored whether these same risk factors influence decline once individuals 
have a dementia diagnosis. Our study is a step towards filling that void and 
expands on previous efforts to identify predictors of decline.  
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Consistent with other studies, our results indicate that African Americans 
compared to whites have greater cognitive impairment at the time of diagnosis. In 
our study, African Americans and whites have similar ages at time of diagnosis 
indicating African Americans may develop dementia at earlier ages.  Others have 
noted that African Americans are more likely to be diagnosed later in the course 
of the disease and have a higher prevalence of dementia at all ages compared to 
whites.58,73 Our results contribute to the literature identifying disparities in 
dementia care and highlight the need for additional research on the mechanisms 
through which race impacts dementia outcomes. 
Racial differences persisted for the measure of functional ability but in the 
opposite direction. At time of diagnosis, African Americans had less functional 
dependence than whites.  It is not entirely clear why this is the case. One 
explanation may be that as family caregivers assess functional ability, there may 
be different interpretations among African Americans and whites.58 While we 
controlled for informant type, due to sparse data we were unable to determine 
the effect of an interaction between informant and race.    
Region of residence was a significant predictor of change in the cognitive, 
functional, and behavioral/psychological models. Our measure of region is broad, 
but likely captures differences in the recruiting and referral practices of providers 
within an ADCs region. 
In our study, the annual rate of change in cognition in the first year was -
1.518 MMSE points. This is comparable to recently published findings from 
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Tschanz and colleagues which used population-based data from the Cache 
County Study on Memory in Aging to evaluate trajectories of dementia patients 
and reported a mean annual rate of change of -1.500 MMSE points.41 However, 
unlike our study they did not account for racial differences or control for clinical 
factors.  
MMSE changes >2 are considered clinically meaningful.74 In our study, 
change in cognitive function in the first year is borderline clinically significant, but 
over time the cumulative effect is clearly clinically meaningful. By the third year 
post-diagnosis patients begin experiencing annual clinically meaningful cognitive 
declines.    
Studies have reported conflicting results for the effect of vascular risk 
factors on cognitive decline.64,75,76 Our results indicate that the presence of 
vascular risk factors (history of hypertension and congestive heart failure) result 
in a slower decline.  This may be indicative of differences between individuals 
with Alzheimer’s disease and vascular dementia.76,77  
Functional ability worsened by 3.464 FAQ points in the first year. Without 
established clinical thresholds it is difficult to conceptualize what this change 
represents. One interpretation is that within the first year an average individual 
developed three additional functional limitations. In the immediate years post 
diagnosis individuals experienced steep functional declines, but over time the 
rate of decline decreased. This finding contrasts with the pattern observed for 
cognitive and behavioral/psychological trajectories. The pattern of functional 
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decline may be explained by the fact that the FAQ predominately measures 
instrumental activities of daily living which are complex and result in losses of 
independence earlier in the disease course compared to losses in activities of 
daily living. 
 Behavioral/psychological symptoms worsened by 0.354 NPI points in the 
first year. This represents a small change and is not likely to be clinically 
meaningful. The most troubling behavioral/psychological symptoms are more 
common in the moderate to advanced stages of the disease, which is illustrated 
by the sharp increase in the NPI-Q score as a patient’s disease progresses.57,78 
Cognitive status was the only clinical characteristic to predict change in 
behavioral symptoms over time, but a history of psychiatric problems or 
hypertension was associated with more behavioral symptoms at diagnosis. To 
our knowledge the NPI-Q has not be used to evaluate behavioral trajectories in 
dementia, but conceptually our analysis differs from others by incorporating 
cognitive status and race as explanatory variables.41,61,78  
Our study has some limitations. Although it uses national data from ADCs, 
it is not nationally representative. Compared to a nationally representative 
sample, our sample is more educated and white but the average age at time of 
diagnosis is similar.41,62,79 Additionally, our cognitive trajectories are consistent 
with a study using a population-based sample lending support to the validity of 
our findings.41,63-66 Other limitations were that we did not account for the effect of 
APOE ε4 allele. Finally, to evaluate non-linear change we limited our analysis to 
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individuals with at least three observations and complete data at baseline. This 
may limit the generalizability of results as patients with fewer observations maybe 
sicker.  
In conclusion, our study finds that sociodemographic characteristics and 
clinical co-morbidities predict cognitive and functional changes over time in newly 
diagnosed dementia patients.  Cognition status is the only factor to predict 
behavioral/psychological changes over time. Our results provide a means of 
identifying individuals at risk of faster decline and facilitate care planning by 
providers and caregivers for different dementia profiles.  
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3.6 Tables 
Table 3.6.1 Baseline sample characteristics 
Characteristics  n=457 
Age in Years at Diagnosis, M (SD) 79.91 (6.26) 
Male, N (%) 251 (55) 
Years of Education, M (SD) 15.37 (2.91) 
Race  
White, N (%) 396 (87) 
African American, N (%) 39 (8) 
Other, N (%) 22 (5) 
Marital Status at Diagnosis  
Married, N (%) 327 (71) 
Widowed, N (%) 100 (22) 
Other, N (%) 30 (7) 
Region of Residence  
Northeast, N (%) 85 (19) 
South, N (%) 28 (6) 
West, N (%) 120 (26) 
Midwest, N (%) 51 (11) 
Not Specified, N (%) 173 (38) 
Place of Residence at Diagnosis  
Community Dwelling, N (%) 440 (96) 
Facility, N (%) 17 (4) 
Informant Relationship   
Spouse, N (%) 291 (64) 
Other Family Member, N (%)  129 (28) 
Other, N (%) 37 (8) 
Comorbidities   
 26 
Ever Hypertension, N (%) 311 (68) 
Ever Diabetes, N (%) 64 (14) 
Ever Congestive Heart Failure, N (%) 29 (6) 
Ever Hypercholesterolemia, N (%) 316 (69) 
Ever Stroke, N (%) 47 (10) 
Ever Psychiatric Problems, N (%) 50 (11) 
MMSE at Diagnosis, M (SD)‡ 24.22 (3.24) 
FAQ at Diagnosis, M (SD)§ 10.89 (7.12) 
NPI-Q at Diagnosis, M (SD)|| 3.90 (3.99) 
Clinical Dementia Rating Score  
None, N (%) 0 (0.00) 
Very Mild, N (%) 275 (60.18) 
Mild, N (%) 171 (37.42) 
Moderate, N (%) 11 (2.41) 
Severe, N (%) 0 (0.00) 
Number of Follow up Visits, M (SD)¶ 4.13 (1.20) 
†Other racial category is comprised of American Indians, Alaskan Natives, Native 
Hawaiians, Asians, and individuals who identify as multiracial  
‡MMSE = Mini-mental State Examination 
§FAQ = Functional Activities Questionnaire 
||NPI-Q = Neuropsychiatric Inventory Questionnaire 
¶ (39% of the sample had 3 observations; 27% of the sample had 4 
observations; 19% of the sample had 5 observations; 15% of the sample had >5 
observations) 
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Table 3.6.2 Average rate of change by year 
Year Cognition – MMSE 
(95% CI) 
Function – FAQ 
(95% CI) 
Behavior – NPI-Q 
(95% CI) 
Diagnosis – Year 1 -1.518 
(-1.745, -1.291) 
3.464 
(3.131, 3.798) 
0.354 
(0.123, 0.585) 
Year 1 – Year 2 -1.748 
(-1.914, -1.583) 
3.111 
(2.898, 3.322) 
0.485 
(0.338, 0.632) 
Year 2 - Year 3 -1.979 
(-2.173, -1.785) 
2.778 
(2.584, 2.972) 
0.637 
(0.483, 0.792) 
Year 3 – Year 4 -2.209 
(-2.495, -1.923) 
2.467 
(2.156, 2.778) 
0.811 
(0.558, 1.064) 
Year 4 – Year 5 -2.440 
(-2.840, -2.040) 
2.178 
(1.700, 2.660) 
1.007 
(0.624, 1.391) 
Year 5 – Year 6 -2.671 
(-3.193, -2.148) 
1.911 
(1.234, 2.588) 
1.225 
(0.695, 1.754) 
Year 6 – Year 7 -2.901 
(-3.549, -2.253) 
1.666 
(0.775, 2.557) 
1.464 
(0.776, 2.152) 
Year 7 – Year 8 -3.132 
(-3.907, -2.356) 
1.441 
(0.319, 2.564) 
1.724 
(0.867, 2.582) 
Notes: Estimates are based on the fully adjusted trajectory model holding 
covariates at their sample mean. Negative MMSE (Mini-mental State 
Examination) slopes represent a decline in cognitive ability. Positive FAQ 
(Functional Activities Questionnaire) slopes represent a decline in functional 
ability. Positive NPI-Q (Neuropsychiatric Inventory Questionnaire) slopes 
represent an increase in behavioral/psychological symptoms. 
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Table 3.6.3 Parameter estimates of cognitive trajectories (n=457) 
  Effects 
Unadjusted 
Cognition (MMSE) 
Adjusted 
Cognition 
(MMSE) 
Intercept 24.295*** 20.328*** 
(24.006, 24.585) (15.849, 24.807) 
Time -1.374*** -3.847*** 
 (-1.652, -1.096) (-6.049, -1.644) 
Time2 -0.127*** -0.115*** 
 
(-0.193, -0.060) (-0.181, -0.050) 
Age of Onset (Years) 
 
0.001 
 
(-0.046, 0.048) 
Age of Onset (Years) * Time 
 
0.031* 
 
(0.004, 0.058) 
Male  
 
0.231 
 
(-0.366, 0.827) 
Years of Education 
 
0.236*** 
 
(0.141, 0.331) 
Race (ref = White)   
African American 
 
-1.629** 
 
(-2.640, -0.618) 
Other 
 
-0.274 
 
(-1.558, 1.010) 
Marital Status (ref = Widowed)   
Married 
 
-0.582 
 
(-1.241, 0.077) 
Other 
 
-0.039 
 
(-1.070, 0.991) 
Region of Residence (ref = Northeast)   
 29 
South  0.025 
 (-1.245, 1.294) 
West  -1.192** 
 (-2.015, -0.368) 
Midwest  1.197* 
 (0.166, 2.228) 
Not Specified   -0.192 
 (-0.971, 0.587) 
Region of Residence (ref = Northeast) 
* Time 
 
 
South   -0.352 
 (-1.109, 0.405) 
West  -0.743** 
 (-1.239, -0.247) 
Midwest  0.082 
 (-0.521, 0.686) 
Not Specified   -0.281 
 (-0.743, 0.180) 
Community-dwelling in Previous Time 
Period (ref = Facility) 
 
0.474 
 
(-0.393, 1.341) 
Ever Hypertension 
 
0.418 
 
(-0.193, 1.029) 
Ever Hypertension * Time 
 
0.371* 
 
(0.021, 0.721) 
Ever Diabetes   -0.216 
 (-1.030, 0.597) 
Ever Congestive Heart Failure   0.207 
  (-0.923, 1.337) 
Ever Congestive Heart Failure * Time  0.698* 
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  (0.031, 1.366) 
Ever Stroke  -0.315 
  (-1.145, 0.515) 
Ever Hypercholesterolemia  0.249 
 (-0.362, 0.861) 
Ever Psychiatric Problems  0.794 
  (-0.086, 1.674) 
Notes: MMSE = Mini-mental State Examination (scored 0–30). Higher scores 
indicate greater cognitive abilities.  
* p <0.05. ** p<0.01. *** p<0.001. 
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Table 3.6.4 Parameter estimates of functional trajectories (n=457) 
Effects 
Unadjusted 
Function (FAQ) 
Adjusted 
Function (FAQ) 
Intercept 10.852*** 31.529*** 
 
(10.207, 11.497) (22.807, 40.251) 
Time 3.907*** 2.028** 
 (3.491, 4.324) (0.574, 3.481) 
Time2 -0.235*** -0.279*** 
 
(-0.320, -0.149) (-0.371, -0.187) 
Cognitive Status (MMSE) 
 
-0.404*** 
  
(-0.520, -0.288) 
Cognitive Status (MMSE) * Time -0.031 
 (-0.067, 0.004) 
Age of Onset (Years) 
 
-0.016 
  
(-0.101, 0.069) 
Male 
 
-2.273*** 
  
(-3.375, -1.172) 
Years of Education 
 
-0.123 
  
(-0.324, 0.077) 
Years of Education * Time 0.056 
  (-0.004, 0.116) 
Race (ref = White)   
African American 
 
-3.520*** 
 
 
(-5.329, -1.711) 
Other 
 
-0.106 
  
(-2.399, 2.188) 
Marital Status (ref = Widowed)  
Married 
 
-1.174 
 
 
(-2.554, 0.207) 
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Other 
 
-0.326 
  
(-2.153, 1.502) 
Region of Residence (ref = 
Northeast)   
South  -0.011 
  (-2.273, 2.250) 
West  1.779* 
  (0.304, 3.253) 
Midwest  -2.221* 
  (-4.046, -0.396) 
Not Specified  0.048 
  (-1.331, 1.427) 
Community-dwelling in Previous 
Time Period (ref = Facility)  
-4.519*** 
(-6.890, -2.147) 
Community-dwelling in Previous 
Time Period (ref = Facility)* Time 
 1.096** 
 (0.359, 1.833) 
Informant Relationship (ref = 
Spouse)   
Other Family Member  -0.944 
  (-2.210, 0.321) 
Other  -1.677 
  (-3.442, 0.088) 
Ever Hypertension 
 
0.018 
 
 
(-1.074, 1.111) 
Ever Diabetes 
 
1.057 
 
 
(-0.632, 2.746) 
Ever Diabetes * Time 
 
-0.535* 
 
(-1.062, -0.008) 
Ever Congestive Heart Failure 0.307 
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  (-1.704, 2.318) 
Ever Stroke  2.214** 
  (0.798, 3.630) 
Ever Hypercholesterolemia  -1.281* 
  (-2.381, -0.181) 
Ever Psychiatric Problems  -0.710 
  (-2.288, 0.869) 
Notes: FAQ = Functional Activities Questionnaire (scored 0–30). Higher scores 
indicate more functional limitations.  
* p <0.05. ** p<0.01. *** p<0.001. 
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Table 3.6.5 Parameter estimates of behavioral/psychological trajectories (n=457) 
Effect 
Unadjusted  
Behavior (NPI)  
Adjusted 
Behavior (NPI) 
Intercept 3.839*** 10.593*** 
 (3.481, 4.198) (5.364, 15.822) 
Time 0.461** 1.256** 
 
(0.165, 0.757) (0.488, 2.024) 
Time2 -0.001 0.002 
 
(-0.068, 0.066) (-0.069, 0.073) 
Cognitive Status (MMSE)  
 
-0.073 
 
 
(-0.149, 0.003) 
Cognitive Status (MMSE) * Time 
 
-0.031* 
  
(-0.057, -0.006) 
Age of Onset (Years) 
 
-0.081** 
  
(-0.134, -0.029) 
Male  
 
0.168 
 
 
(-0.576, 0.911) 
Male * Time -0.258 
  (-0.562, 0.046) 
Years of Education 
 
-0.045 
  
(-0.151, 0.060) 
Race (ref = White)  
African American 
 
-0.485 
 
 
(-1.601, 0.630) 
Other 
 
-0.123 
  
(-1.540, 1.295) 
Marital Status (ref = Widowed)   
Married 
 
0.100 
 
 
(-0.814, 1.014) 
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Other 
 
0.945 
  
(-0.236, 2.127) 
Region of Residence (ref = 
Northeast)   
South  1.776* 
  (0.383, 3.170) 
West  0.776 
  (-0.132, 1.685) 
Midwest  0.778 
  (-0.357, 1.914) 
Not Specified  1.269** 
  (0.413, 2.124) 
Community-dwelling in Previous 
Time Period (ref = Facility)  
0.846 
 
(-0.111, 1.803) 
Informant Relationship (ref = 
Spouse)   
Other Family Member  0.112 
  (-0.810, 1.034) 
Other  -0.352 
  (-1.729, 1.025) 
Informant Relationship (ref = 
Spouse) * Time   
Other Family Member  -0.304 
  (-0.627, 0.019) 
Other  -0.420 
  (-0.894, 0.054) 
Ever Hypertension  0.738* 
  (0.064, 1.413) 
Ever Diabetes  0.520 
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  (-0.375, 1.415) 
Ever Congestive Heart Failure  0.624 
  (-0.616, 1.864) 
Ever Stroke  1.121 
  (-0.156, 2.398) 
Ever Stroke * Time  -0.516 
  (-1.064, 0.032) 
Ever Hypercholesterolemia  -0.617 
  (-1.291, 0.056) 
Ever Psychiatric Problems 
 
1.319** 
  
(0.346, 2.291) 
Notes: NPI-Q = Neuropsychiatric Inventory Questionnaire severity score (scored 
0–36). Higher scores indicate more severe behavioral/psychological symptoms.  
* p <0.05. ** p<0.01. *** p<0.001. 
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3.7 Figure 
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Figure 3.7.1 Predicted cognitive, functional, and behavioral trajectories 
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Figure 3.7.1 Legend: Fully adjusted model trajectories based on sample mean values for covariates (dashed-lines 
represent 95% CI) of cognition (1), function (2), and behavioral/psychological symptoms (3). Higher MMSE (Mini-mental 
State Examination) scores indicate greater cognitive abilities. Higher FAQ (Functional Activities Questionnaire) scores 
indicate more functional limitations. Higher NPI-Q (Neuropsychiatric Inventory Questionnaire) scores indicate greater 
severity of behavioral/psychological symptoms. 
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Chapter 4: Effects of Cognition, Function, and Behavior 
on Medicare Expenditures and Health Care Utilization  
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4.1 Overview   
BACKGROUND: Clinical features of dementia (cognition, function, and 
behavioral/psychological symptoms) may differentially affect Medicare 
expenditures/health care utilization.  
METHODS: We linked cross-sectional data from the Aging, Demographics, and 
Memory Study to Medicare data to evaluate the association between dementia 
clinical features among those with dementia and Medicare expenditures/health 
care utilization (n=234). Cognition was evaluated using the Mini-Mental State 
Examination (MMSE). Function was evaluated as the number of functional 
limitations (0-10).  Behavioral/psychological symptoms were evaluated as the 
number of symptoms (0-12). Expenditures were estimated with a generalized 
linear model (log-link and gamma distribution). Number of hospitalizations, 
institutional outpatient visits, and physician visits were estimated with a negative 
binomial regression. Medicare covered skilled nursing days were estimated with 
a zero-inflated negative binomial model.   
RESULTS: Cognition and behavioral/psychological symptoms were not 
associated with expenditures. Among individuals with <7 functional limitations, 
one-additional limitation was associated with $123 (95% CI: $19-$227) additional 
monthly Medicare spending. Better cognition and poorer function were 
associated with more hospitalizations among those with an MMSE<3 and <6 
functional limitations, respectively. Behavioral/psychological symptoms had no 
effect on hospitalizations. Poorer function and fewer behavioral/psychological 
symptoms were associated with more skilled nursing among individuals with 1-to-
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7 functional limitations and >4 symptoms, respectively. Cognition had no effect 
on skilled nursing care. No clinical feature was associated with institutional 
outpatient care. Of individuals with an MMSE <15, poorer cognition was 
associated with fewer physician visits. Among those with >6 functional limitations, 
poorer function was associated with fewer physician visits.  
CONCLUSIONS: Poorer function, not cognition or behavioral/psychological 
symptoms, was associated with higher Medicare expenditures. 
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4.2 Introduction 
Dementia is one of the most costly diseases to society,13,17,18,80 because 
persons with dementia can live more than 10 years with the disease while 
experiencing a complex set of clinical features including cognitive and functional 
decline and behavioral and psychological symptoms.17,18,59,61,81  
Recent studies from RAND and others have demonstrated that persons 
with dementia have higher health care costs and use more health care services 
than those without dementia,13,17,18,59,61,80,81 though less is known about how the 
clinical features of dementia affect the cost of dementia care. This study extends 
the literature by evaluating the association between the clinical features with cost 
among those with dementia. Understanding the separate contributions of 
cognition, function, and behavioral/psychological symptoms to the cost of 
dementia care and to the types of health care services used (e.g., number of 
hospitalizations) can provide insight into the possible mechanisms that drive 
higher costs, and informs the development of services, programs, and 
interventions to reduce such costs.  
 Prior studies have found that the total cost of caring for a person with 
dementia and the number of health care services used generally increases with 
disease severity.13,16-18,35,45,46,80,82-85 Despite employing different methodologies, 
most prior studies have noted that poorer function is associated with more 
spending and more health care utilization (hospitalizations, emergency room 
visits, and outpatient treatment).13,16,59,61,80,81  Several of those studies have 
shown that within a disease stage (e.g., mild, moderate, and severe) costs and 
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resource utilization are moderated by clinical features. For example, results from 
a study using data from the National Long Term Care Survey found that within a 
level of dementia severity (severe and moderate) costs were ten times greater 
among those with five functional limitations compared to those with no limitations. 
13,17,18,80 Results are inconclusive regarding the effect of cognition and 
behavioral/psychological symptoms with studies finding significant and 
nonsignificant associations between these clinical features and cost/health care 
utilization.16,29,45,83 Many studies have important methodological limitations 
including using non-representative data, relying on claims data to determine 
dementia status, and not separating expenditures by payer (e.g., individual out-
of-pocket spending or Medicare expenditures). Relying on claims data to identify 
dementia cases may result in an overestimation of Medicare cost attributable to 
dementia.86,87 Identifying the source of cost by payer is important for 
policymaking and budgetary planning because the responsibilities and the 
amount of cost vary by payer. Our study addresses these limitations by using 
nationally representative data, identifying dementia cases based on a clinical 
diagnosis, and evaluating cost from a Medicare perspective. 
 In a prior analysis, we used the nationally representative Aging, 
Demographics, and Memory Study (ADAMS), a subsample of the Health and 
Retirement Study (HRS), to evaluate the effect of cognition, function, and 
behavioral/psychological symptoms on out-of-pocket expenditures and time 
spent receiving informal care for persons with dementia.88 We found that poorer 
function was associated with more out-of-pocket spending and more caregiving, 
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and an increase in the number of behavioral/psychological symptoms was 
associated with more caregiving. In the current analysis, we use ADAMS to 
evaluate the effect of cognition, function, and behavioral/psychological symptoms 
on Medicare expenditures and health care utilization (number of inpatient 
admissions, number of Medicare covered skilled nursing facility days, number of 
outpatient institutional visits, and number of physician visits) for persons with 
dementia.  
 
4.3 Methods 
4.3.1 Study Design and Data  
We used cross-sectional data from ADAMS (Wave A). The ADAMS 
subsample was drawn from HRS (individuals ≥70), and ADAMS was specifically 
designed to collect clinical measures related to cognitive health and dementia. 
Unlike the core HRS, ADAMS contains a clinical diagnosis of dementia and 
measures related to BPS.89 ADAMS Wave A assessments were conducted 
between 2001 and 2003. During the ADAMS in-home assessment, a trained 
nurse and neuropsychology technician administered a standardized protocol that 
included measures to assess cognition, function, and behavioral/psychological 
symptoms. Following the ADAMS assessment, an independent consensus panel 
comprised of a geropsychiatrist, neurologist, neuropsychologist, and internists 
reviewed respondent medical records and responses to the in-home assessment 
to determine if an individual had normal cognitive function, cognitive impairment 
not dementia, or dementia. Diagnosis was based on published criteria including 
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DSM-III-R and DSM-IV.89 Although diagnostic categories (e.g., Alzheimer’s 
dementia) are provided in the data, we did not limit our analysis to a specific type 
of dementia because diagnosis is subject to misclassification.68,69  
In addition to using the data in the ADAMS survey, we linked respondents 
to their nearest HRS survey (mean time between surveys 8.14 months) to obtain 
additional information on comorbidities that were not captured in the ADAMS 
survey (RAND HRS version N - the RAND HRS Data File is an easy to use data 
set based on the HRS data. The RAND HRS file combines multiple HRS files into 
a single data file and contains imputations for missing data. The RAND HRS file 
was developed at RAND with funding from the National Institute on Aging and 
the Social Security Administration).89 That is, ADAMS provided a clinical 
diagnosis of dementia, measures for cognition, function, and 
behavioral/psychological symptoms, and demographic information. HRS 
provided detailed data on comorbidities.  
More than 80% of ADAMS respondents consented to linking their survey 
data with CMS Medicare data. We combined ADAMS survey respondents with 
their corresponding CMS Medicare data. Specifically, we linked the cross-
sectional ADAMS assessment with an annual summary Medicare file. We 
included only annual Medicare expenditures and health care utilization for the 
year in which the subject was interviewed in ADAMS. The summary Medicare file 
aggregates Part A & B claims and enrollment data on an annual basis and was 
developed for use with HRS/ADAMS. 
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Our sample was restricted to ADAMS respondents identified as having 
dementia with complete data on the variables of interest and who were 
continually enrolled in fee-for-service Medicare for the year of the ADAMS 
assessment.  The University of Minnesota institutional review board approved 
this study.  
 
4.3.2 Measures of Clinical Features of Dementia 
Dementia was modeled using cognition, function, and 
behavioral/psychological symptoms.59,61 All three clinical features were evaluated 
during the ADAMS in-home clinical assessment. Cognition was evaluated using 
the Mini-Mental State Examination (MMSE).70 The MMSE is scored from 0–30 
with lower scores indicating greater cognitive impairment.  
Function was evaluated as the total number of functional limitations (0–10) 
an individual had difficulty performing (yes/no) among the following domains: 1) 
handling small sums of money, 2) handling complicated financial transactions, 3) 
shopping independently, 4) performing hobbies, 5) carrying out routine 
household tasks, 6) difficulty feeding self, 7) recalling recent events, 8) 
understanding what s/he reads or sees on television, 9) remembering things 
about family and friends, and 10) finding one’s way around familiar streets. 
These domains were specifically chosen as they correspond with the functional 
domains assessed in the Functional Activities Questionnaire, one of the few 
standardized measures for assessing functional ability.71  
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Finally, the number of behavioral/psychological symptoms (0–12) was 
identified using the Neuropsychiatric Inventory Questionnaire (NPI).72 The NPI 
asks caregivers to identify if the following behavioral/psychological symptoms 
occurred and if so, its frequency and severity: 1) delusions, 2) hallucinations, 3) 
agitation or aggression, 4) depression, 5) apathy, 6) elation, 7) anxiety, 8) 
disinhibition, 9) irritability, 10) motor disturbance, 11) nighttime behaviors, and 
12) change in appetite and eating. For our analyses, we generated a summary 
score reflecting the total number of behavioral/psychological symptoms endorsed 
by a caregiver as being present. The number of behavioral/psychological 
symptoms is associated with resource utilization.90 
 
4.3.3 Outcomes 
We calculated average monthly Medicare expenditures (annual 
expenditures in the year of the ADAMS assessment/12). Medicare expenditures 
were converted to 2015 United States dollars using the medical care component 
of the Consumer Price Index. To provide insight into the potential drivers of 
Medicare expenditures we also evaluated average monthly Medicare health care 
utilization: number of inpatient admission, number of Medicare covered skilled 
nursing facility days, number of institutional outpatient visits, and number of 
physician visits.  The number of inpatient admissions represents unique hospital 
stays in which an individual was designated as being an inpatient. To receive 
Medicare covered skilled nursing an individual had to have a qualifying inpatient 
stay and be hospitalized for ≥3 nights. We evaluated the number of inpatient 
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admissions since inpatient care is reimbursed based on an episode of care. In 
contrast, we evaluated the number of skilled nursing care days since Medicare 
reimburses for skilled nursing care based on days of care. Institutional outpatient 
utilization represents unique outpatient episodes of care for events such as 
observation services and outpatient surgery. The number of physician visits 
represents unique office visits for evaluation and management services. These 
unique physician visits can include care that occurs during an outpatient 
institutional visit. 
 
4.3.4 Covariates 
We controlled for confounders in our model to separate the extra Medicare 
cost associated with the clinical features from other factors that might impact 
cost. Confounders were identified from the literature based on their prior 
empirical associations with health care costs and the clinical features of dementia 
and included age, gender, race, marital status, and total number of chronic 
conditions (0–8) among the following: stroke, diabetes, heart problems, 
hypertension, lung disease, cancer, psychiatric problems, or arthritis.17,46,83,91   
 
4.3.5 Statistical Analysis 
We estimated separate adjusted multivariate regression models for each 
outcome of interest (five adjusted models in total): Medicare expenditures, 
number of inpatient admission, number of Medicare covered skilled nursing 
facility days, number of outpatient institutional visits, and number of physician 
visits.  
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Due to skewness in Medicare expenditures we estimated a generalized 
linear model with a log-link and gamma distribution. All measures of health care 
utilization, except the number of skilled nursing days, were estimated with a 
negative binomial regression.  A zero-inflated negative binomial model was used 
to evaluate the number of skilled nursing days since the data exhibits excessive 
zeros. In preliminary analyses, the zero-inflated model failed to coverage when 
all covariates were included in the zero-inflation portion of the model.  The final 
zero-inflated model included all covariates in the count portion of the model, and 
only individual demographic characteristics in the inflation portion of the model.  
For each model, we separately predicted the outcome and calculated the 
average marginal effects at representative values for each clinical feature (e.g., 
marginal effects when number of functional limitations was 0, 1, 2,…,10) to 
provide insight into their differential effect on the outcome at levels of feature 
severity. That is, we sought to understand how a change in cognition (1 point 
decline), function (1 point increase), or behavioral/psychological symptoms (1 
point increase) affected the outcome when the clinical features took on different 
values.  
All analyses were conducted using ADAMS survey weights and Stata 
version 12 survey commands (Stata, College Station, TX).  
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4.4 Results 
4.4.1 Sample Characteristics 
Of the 308 individuals in ADAMS Wave A with a diagnosis of dementia, 
234 had complete data on the variables of interest. Comparison between those 
excluded/included from the analysis showed no statistically significant differences 
(Table A4.1; Figure A4.2 shows the derivation of the analysis sample). The 
mean age of the 234 individuals with dementia was 84.12 (SD 10.87) (Table 
4.6.1); individuals had a mean MMSE score of 16.06 (SD 11.94), and had an 
average of 6.18 (SD 3.71) functional limitations and 2.63 (SD 4.23) 
behavioral/psychological symptoms. 
 
4.4.2 Medicare Expenditures 
An individual with dementia had average-adjusted monthly Medicare 
expenditures of $1,041 (95% CI: $771, $1,311).  Cognition and 
behavioral/psychological symptoms were not significantly associated with 
Medicare expenditures and this was consistent across levels of severity (Figure 
A4.3).  Poorer function was associated with significantly more Medicare spending 
(Table 4.6.2).  The effect of function on Medicare expenditures increased with 
greater levels of functional impairment, but this effect was only significant among 
those with <7 functional limitations (Figure A4.3). Specifically, an increase from 
one to two functional limitations was associated with $75 (95% CI: $48, $102) 
additional Medicare spending per month, while an increase from five to six 
limitations was associated with $140 (95% CI: $22, $257) additional spending per 
month. The average marginal effect of one-additional functional limitation on 
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Medicare expenditures among those with <7 limitations was $123 (95% CI: $19, 
$227).  
 
4.4.2 Health Care Utilization 
On average, individuals had 0.05 (95% CI: 0.04, 0.06) inpatient admission 
per month. A one-unit decline in cognition was associated with -0.001 (95% CI: -
0.003, 0.00) fewer inpatient admissions among those with an MMSE score <3 
(Figure A4.4). One-additional functional limitation was significantly associated 
with 0.006 (95% CI: 0.001, 0.012) more inpatient admissions among those with 
<6 limitations (Figure A4.4). Behavioral/psychological symptoms were not 
associated with inpatient admissions (Table 4.6.2). 
 Individuals had an average of 0.42 (95% CI: 0.21, 0.63) Medicare covered 
skilled nursing care days per month. Cognition was not associated with skilled 
nursing care. Poorer function was associated with 0.10 (95% CI: 0.02, 0.18) 
more Medicare skilled nursing care days among those with 1-to-7 functional 
limitations (Figure A4.5).  One-additional behavioral/psychological symptom was 
associated with -0.07 (95% CI: -0.12, -0.01) fewer Medicare covered skilled 
nursing days among those with >4 symptoms. 
 Individuals had an average of 0.44 (95% CI: 0.34, 0.54) institutional 
outpatient visits per month. No clinical feature was associated with institutional 
outpatient care (Table 4.6.2, Figure A4.6). 
Finally, individuals had an average of 0.39 (95% CI: 0.32, 0.48) physician 
visits (evaluation and management services) per month. A one-unit decline in 
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cognition was associated with -0.01 (95% CI: -0.01, 0.00) fewer physical visits 
among those with an MMSE score <15 (Figure A4.7). Similarly, poorer function 
was associated with -0.02 (95% CI: -0.04, 0.00) fewer physician visits among 
those with >6 functional limitations. Behavioral/psychological symptoms were not 
associated with number of physician visits.  
 
4.5 Discussion  
We used nationally representative data to estimate the effect of three key 
clinical features of dementia - cognition, function, and behavioral/psychological 
symptoms – on Medicare expenditures and health care utilization.  Poorer 
function, but not cognition or behavioral/psychological symptoms, was 
significantly associated with more Medicare spending. Our results complement 
prior studies that have found poorer function is associated with higher cost, and 
that among individuals with dementia, function is potentially a more important 
predictor of costs than cognition.16,35,45,80,83 Unlike prior studies, we explicitly 
evaluated the differential effect of the severity of dementia clinical features on 
Medicare expenditures and health care utilization.  We further extend results by 
using nationally representative data and not relying on claims data to determine if 
an individual has dementia.  
The marginal effect of function on Medicare expenditures increased with 
greater levels of functional impairment; however, among those with ≥7 limitations 
the effect of an additional limitation on expenditures was no longer significant.  
The significant effect of poorer function among those with <7 limitations was 
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enough to generate an overall significant average effect.  The reason for lack of 
significance of the marginal effect for more severe levels of functional impairment 
are not entirely clear, but may reflect sparse data for those with ≥7 limitations. 
Clinically, one potential explanation is that with more severe functional 
limitations, which may be associated with more severe dementia, medical care 
may be less aggressive reflecting advance care directives.92  
The effect of function on Medicare expenditures appears to be driven, in 
part, through the effect of poorer function on more inpatient admissions among 
individuals with <6 limitations. While the effect of an additional functional 
limitation on inpatient admissions is low (0.006), this equates to a 12% increase 
in monthly inpatient admissions (0.05 average monthly inpatient admissions) and 
has potential cost implications. Others studies, including Zhu et al. and Small et 
al., also reported that poorer function was associated with more inpatient 
care.16,45 Importantly, many dementia related hospitalizations are potentially 
avoidable.93  Although we found that more sever cognitive limitations (MMSE<3) 
were associated with fewer hospitalizations, this finding is likely not clinically or 
policy significant given the small effect size (~2% decline in admissions) and 
narrow population for which findings apply (only individuals with MMSE<3).  
Individuals with dementia utilize Medicare skilled nursing care at greater 
rates than individuals without dementia.94 However, to our knowledge our study 
is first to investigate the relationship between dementia clinical features and 
Medicare covered skilled nursing utilization. The effect of function on Medicare 
expenditures also appears driven by the relationship between poorer function 
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and more skilled nursing care among individuals with 1-to-7 limitations. In 
contrast, among those with >4 behavioral/psychological symptoms, one-
additional symptom was associated with less skilled nursing care. The negative 
effect of behavioral/psychological symptoms on Medicare skilled nursing care 
may reflect that a hospitalization triggered by a behavioral/psychological 
symptom makes a person with dementia a poorer candidate for Medicare 
covered skilled nursing care as opposed to placement in a nursing home. 
However, we were unable to test this hypothesis since our data was limited to 
observing only Medicare covered skilled care.  
We did not find an effect between the clinical features and institutional 
outpatient care. However, unlike several other studies, we found that poorer 
cognition among those with an MMSE score <15 and poorer function among 
those with >6 limitations were associated with fewer physician visits.16,45 Again it 
is important to note that physician visits can include care that occurs during 
institutional outpatient care. The average effect of cognition (-0.01) and function 
(-0.02) on physician visits were low and equate to a ~5% decline in visits. The 
negative association between physician care and more severe cognitive and 
functional limitations may be due to the previously stated hypothesis of the use of 
less aggressive care with more severe disease reflecting advance care 
directives.92   
There are potential mechanisms for reducing Medicare spending, inpatient 
admissions, and skilled nursing care associated with poorer function in 
individuals with dementia. Foremost, functional limitations can be managed by 
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effective ambulatory care, and by formal and informal caregivers.95-97 Better 
management of functional limitations may translate into lower Medicare 
expenditures through less inpatient and skilled nursing utilization. Additionally, 
ongoing post-acute care payment reform may result in a reduction in Medicare 
payments and overall skilled nursing utilization, and potentially render the effect 
of function on skilled nursing utilization null.98  
We did not find a significant relationship between the number of 
comorbidities and Medicare spending. In the literature, the effect of comorbidities 
on Medicare spending among those with dementia is inconclusive. Some studies 
have found that among those with dementia comorbidities are not associated 
with more Medicare spending, some have found that only specific comorbidities 
are associated with spending, and some have found an association between any 
comorbidities and spending.16,80,99 Future studies with larger sample sizes are 
needed to investigate the interaction between comorbidities and the clinical 
features.  
Our study has several limitations. We used cross-sectional data, and were 
not able to evaluate the effect of the clinical features on costs over time within a 
person. Due to lack of data, our evaluation of Medicare expenditures did not 
include those for prescription medication (Part D). The likely result is an 
underestimation of total Medicare cost. Conceptually we believe we controlled for 
key confounders; however, it is possible that we may have omitted confounders 
from our analyses. If an omitted confounder is strongly correlated with the clinical 
features and outcomes then our results will be biased. Finally, in this analysis we 
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did not evaluate the effect of the clinical features of dementia on the health and 
Medicare expenditures of family caregivers.  
In conclusion, poorer function, but not cognition or 
behavioral/psychological symptoms, was associated with more Medicare 
expenditures. The effect of function on Medicare expenditures was 
predominantly due to the effect of poorer function on expenditures among those 
with <7 limitations. Poorer function was also associated with greater inpatient and 
skilled nursing care among those with <6 and 1-to-7 limitations, respectively. 
Poorer cognition among those with an MMSE<3 was associated with fewer 
inpatient admission. Behavioral/psychological symptoms were not associated 
with inpatient admissions, but more behavioral/psychological symptoms among 
those with >4 symptoms were associated with less skilled nursing care. No 
clinical feature was associated with institutional outpatient care. Poorer cognition 
among those with an MMSE <15 and poorer function among those with >6 
limitations were associated with less physician visits. Interventions that target 
function could reduce Medicare expenditures.  
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4.6 Tables 
Table 4.6.1 Sample characteristics  
 Demographic 
Characteristics* 
 (n=234) 
Mean cognition ± SD (range), MMSE 16.06 ± 11.94 (0-27) 
Mean function ± SD (range) 6.18 ± 3.71 (0-9) 
Mean number of behavioral/psychological 
symptoms ± SD (range) 
2.63 ± 4.23 (0-10) 
Mean age ± SD (range), y 84.12 ± 10.87 (70-110) 
Male,  % 35.37 
Non-Caucasian, % 18.88 
Married, % 21.76 
Mean number of comorbidities ± SD 
(range) 
2.96 ± 2.67 (0-7) 
 
Notes. MMSE = Mini-Mental State Examination; *Aging Demographics and 
Memory Study sample weights were used. 
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Table 4.6.2 Regression coefficients (95% confidence interval) for monthly Medicare expenditures/health care utilization 
(n=234)* 
 Medicare 
Expenditures 
Number of 
Inpatient 
Admission  
Number of Medicare Covered 
Skilled Nursing Facility 
Covered Days  
Number of 
Institutional 
Outpatient 
Visits  
Number of 
Physician 
Visits† 
(generalized 
linear model 
log link 
gamma 
distribution) 
(negative 
binomial 
model) 
(zero-inflated negative 
binomial model) 
(negative 
binomial 
model) 
(negative 
binomial 
model) 
Inflation Portion Count 
Portion  
  
Intercept   6.37 -4.09 5.76 -0.08 -1.66 -0.27 
(3.06, 9.68) (-7.91, -
0.27) 
(-2.84, 14.35) (-6.37, 6.22) (-5.75, 2.43) (-2.72, 2.18) 
MMSE 0.03 0.04  -0.01 0.02 0.02 
(-0.01, 0.07) (-0.03, 0.10)  (-0.09, 0.06) (-0.02, 0.06) (0.00, 0.05) 
Number of functional 
limitations 
0.15 0.17  0.39 0.02 -0.06 
(0.02, 0.29) (-0.02, 0.36)  (0.13, 0.66) (-0.08, 0.13) (-0.11, -0.01) 
Number of 
behavioral/psychological 
0.03 0.01  -0.16 -0.01 0.02 
(-0.05, 0.10) (-0.09, 0.11)  (-0.31, -0.01) (-0.12, 0.10) (-0.05, 0.08) 
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symptoms  
Age -0.01 -0.01 -0.06 -0.02 0.00 -0.01 
 (-0.05, 0.02) (-0.05, 0.02) (-0.17, 0.05) (-0.08, 0.04) (-0.05, 0.05) (-0.04, 0.01) 
Male 0.46 0.32 -26.01 -1.49 0.63 0.04 
 (-0.07, 0.99) (-0.29, 0.92) (-28.74, -23.27) (-2.60, -0.38) (0.24, 1.01) (-0.37, 0.45) 
Non-Caucasian (ref = 
white) 
0.06 0.04 -0.69 -0.73 0.12 0.03 
(-0.58, 0.69) (-0.49, 0.56) (-2.13, 0.74) (-1.60, 0.13) (-0.34, 0.58) (-0.44, 0.50) 
Married (ref = not 
married) 
-0.41 -0.03 -0.91 -2.12 -0.15 0.67 
(-0.93, 0.10) (-0.57, 0.51) (-3.10, 1.28) (-3.97, -0.27) (-0.91, 0.62) (0.25, 1.10) 
Number of chronic 
conditions  
0.07 0.10 0.10 0.26 0.08 0.06 
(-0.09, 0.22) (-0.10, 0.31) (-0.55, 0.76) (-0.02, 0.53) (-0.10, 0.25) (-0.12, 0.24) 
Notes. MMSE = Mini-Mental State Examination 
*Aging Demographics and Memory Study sample weights were used. 
†Physician visits are for evaluation and management services and can include care that occurs during an institutional 
outpatient institutional visit.  
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Chapter 5: Effects of Cognition, Function, and Behavior 
on Out-of-Pocket Medical and Nursing Home 
Expenditures and Time Caregiving  
 61 
5.1 Overview   
BACKGROUND: Clinical features of dementia (cognition, function, and 
behavioral/psychological symptoms) may differentially affect out-of-pocket 
medical and nursing home (NH) expenditures and informal care received 
(outcomes). 
METHODS:	We used cross-sectional data (Aging, Demographics, and Memory 
Study) to estimate probabilities of experiencing outcomes by clinical features. For 
those experiencing an outcome, we estimated effects of clinical features on the 
amount of the outcome. 
RESULTS: No clinical feature predicted the probability of having out-of-pocket 
medical expenditures. For those with medical expenditures, higher cognition and 
poorer function were associated with more spending. Poorer function predicted 
having out-of-pocket NH expenditures. For those with NH expenditures, no 
clinical feature predicted the amount. Poorer function and a greater number of 
behavioral/psychological symptoms predicted the probability of receiving 
caregiving. For those receiving care, poorer function was associated with more 
caregiving. 
CONCLUSIONS: Clinical features differentially impact outcomes with poorer 
function associated with all types of costs and caregiving received. 
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5.2 Introduction 
Dementia affects more than five million Americans and results in cognitive and 
functional declines and behavioral and psychological symptoms.1,59,61,81 Declines 
in cognition and function combined with behavioral/psychological symptoms 
result in a disproportionate use of formal and informal long-term care.1,17,59,61,100 
Given this increased reliance on care, the direct and indirect costs of dementia 
per patient to society can exceed $50,000 per year.17 A significant portion of 
costs are incurred by families and Medicaid.1,17,18,22,101,102  
The most reliable estimates for the total net cost and net out-of-pocket 
cost of dementia come from two RAND studies that used data from the Health 
and Retirement Study (HRS).17,22 However, these studies did not evaluate the 
independent contributions of each key clinical feature – cognition, function, and 
behavioral/psychological symptoms – to out-of-pocket cost. These clinical 
features may impact out-of-pocket spending by requiring more care to manage 
symptoms, and causing caregivers to spend more time in supervision.  
Prior studies evaluating effects of clinical features on total cost suggest that 
function is an important predictor.16,35,46,83,103 However, results have been 
inconsistent and conflicting for the effects of cognition and 
behavioral/psychological symptoms. Moreover, previous cost studies have 
important limitations including the use of non-representative data sources, lack of 
a clinical diagnosis of dementia to identify the analytic sample, not separating 
medical expenditures from nursing home expenditures, and not disaggregating 
out-of-pocket expenditures from those covered by insurance.13,16,29,35,45,46,83,103 
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Understanding the type of out-of-pocket cost (medical or nursing home 
expenditure) based upon clinical features can assist in care planning and 
developing targeted interventions. 
To address previous research limitations, this study used data from a 
subsample of HRS, the Aging, Demographics, and Memory Study (ADAMS), a 
nationally representative survey of cognitive impairment, to evaluate the effects 
of cognition, function, and behavioral/psychological symptoms on out-of-pocket 
medical and nursing home expenditures and time spent receiving informal 
caregiving.  
 
5.3 Methods 
5.3.1 Study Design and Data 
HRS is a nationally representative longitudinal survey of adults ≥51 
years.104 While the core HRS has measures evaluating cognition and function, 
the survey lacks a clinical diagnosis of dementia and does not contain measures 
related to behavioral/psychological symptoms.  Rather than impute dementia 
status in the full HRS and not have access to measures of 
behavioral/psychological symptoms, we used ADAMS data instead.  The ADAMS 
subsample was drawn from HRS (individuals ≥70 years) and was developed to 
provide population-based data on risk factors, prevalence, outcomes, and costs 
of cognitive impairment and dementia in the US.89 ADAMS respondents 
participated in an in-home clinical assessment during which a trained nurse and 
neuropsychology technician administered a standardized protocol to collect 
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cognitive, functional, and behavioral/psychological measures. Following the in-
home assessment, an independent consensus panel determined if the individual 
had dementia, cognitive impairment not dementia, or normal cognitive function.89 
 We linked ADAMS respondents to their HRS survey to obtain 
sociodemographic variables that were not collected in ADAMS (RAND HRS 
version N - the RAND HRS Data File is an easy to use data set based on the 
HRS data.  The RAND HRS file combines multiple HRS files into a single data 
file and contains imputations for missing data. The RAND HRS file was 
developed at RAND with funding from the National Institute on Aging and the 
Social Security Administration).89 Specifically, in addition to identifying a sample 
of individuals with a dementia diagnosis, ADAMS provided measures for 
cognition, function, and behavioral/psychological symptoms and estimates of 
time spent receiving informal care (Table A5.1 details the data source of model 
variables). HRS data provided estimates of out-of-pocket medical and nursing 
home expenditures and additional sociodemographic information.  
We restricted our sample to ADAMS respondents (Wave A) identified as 
having dementia with complete data on variables of interest (Figure 5.7.1). 
Although our analyses are cross-sectional, there was a lag between the ADAMS 
and HRS assessments (Table 5.6.1 mean lag 7.42 months).  To minimize 
potential bias associated with the lag and to maximize the available sample size, 
we linked ADAMS respondents to their closest available HRS wave (HRS wave 
2000, 2002, or 2004). For out-of-pocket medical and nursing home expenditure 
analyses, but not time receiving care analyses, we excluded individuals who 
 65 
were linked to the 2000 HRS wave (n=18), as HRS combined out-of-pocket 
spending for medical and nursing home care in that wave. After the 2000 wave, 
HRS distinguished between out-of-pocket medical and nursing home 
expenditures. To determine if the linking method impacted the analytic sample, 
we linked ADAMS respondents to the next HRS wave. Comparisons of the 
analytic sample based on linking method revealed no statistically significant 
differences in terms of outcome measures, clinical features, and key confounders 
(Table A5.2 and A5.3) 
 
5.3.2 Measures of Clinical Features of Dementia 
Dementia was modeled using three clinical features, cognition, function, 
and behavioral/psychological symptoms, evaluated in the ADAMS clinical 
assessment.59,61 Cognition was measured using the Mini-Mental State 
Examination (MMSE),70 scored 0–30 with higher scores indicating greater 
cognitive function.   
Function was assessed using an investigator-modified version of the 
Functional Activities Questionnaire (FAQ). The FAQ is a standardized measure 
to evaluate function that is used in other dementia surveys.60 However, as it was 
not used in ADAMS, we identified survey questions that were administered and 
corresponded with the ten functional domains assessed in the FAQ. For each 
domain, we evaluated if the individual had difficulty performing the representative 
tasks (yes/no): 1) handling small sums of money, 2) handling complicated 
financial transactions, 3) shopping independently, 4) performing hobbies, 5) 
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carrying out routine household tasks, 6) difficulty feeding self, 7) recalling recent 
events, 8) understanding what s/he reads or sees on television, 9) remembering 
things about family and friends, and 10) finding one’s way around familiar streets.  
For our analyses, we counted the number of “yes” responses to generate a 
summary score (0–10). Table A5.4 compares the measures used in the FAQ 
with the investigator-developed version from ADAMS.71 
Finally, we evaluated the number of behavioral/psychological symptoms 
that caregivers endorsed as occurring in the past month using the 
Neuropsychiatric Inventory Questionnaire which captures 12 symptoms: 1) 
delusions, 2) hallucinations, 3) agitation/aggression, 4) depression, 5) apathy, 6) 
elation, 7) anxiety, 8) disinhibition, 9) irritability, 10) motor disturbance, 11) sleep, 
and 12) appetite 72.  For each domain, caregivers indicated if the behavior 
occurred (yes/no), and if yes, its frequency and severity. For our analyses, we 
counted the number of “yes” responses to generate a summary score reflecting 
total number of behaviors endorsed (0–12).  The number of 
behavioral/psychological symptoms has been associated with caregiver burden 
and resource utilization.90,105-107  
5.3.3 Outcomes 
We evaluated average monthly out-of-pocket medical care spending, 
average monthly out-of-pocket nursing home spending, and average monthly 
time in receipt of informal caregiving. All costs were converted to 2015 United 
States dollars using the medical care portion of the Consumer Price Index.  
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In the HRS, respondents or proxy respondents, reported out-of-pocket 
expenditures over the previous two-years for nursing home stays, hospital stays, 
medical visits, outpatient surgery, home health care, special services, and dental 
visits. Respondents or proxy respondents also reported out-of-pocket 
prescription drug spending over the previous month.  Proxies responded for 
individuals who were unable to complete the survey without assistance (n=103). 
All spending (expect drug spending) was divided by 24 to estimate 
average monthly out-of-pocket spending.  Measures of out-of-pocket medical 
spending (all categories expect nursing home spending) were summed together. 
Out-of-pocket nursing home spending was kept as a separate outcome measure.  
 ADAMS evaluated time individuals with dementia received informal 
caregiving (informants were queried) in the previous month. The informal time 
caregiving analyses were limited to community-dwelling persons with dementia 
that had a caregiver provide information on time caregiving (Figure 5.7.1, Panel 
B). Three measures of informal time caregiving were evaluated: 1) time spent 
receiving active help for assistance with functional tasks (e.g., cooking meals), 2) 
time spent receiving supervision to ensure safety, and 3) time spent receiving 
active care and supervision combined. Some informants reported providing one 
type of care (e.g., active help) but then had missing responses for the other type 
of care (e.g., supervision). When this occurred, the dyad was included in the 
analysis for which data were available. Consistent with other cost studies, we 
assumed caregivers could provide a maximum of 16 hours of care per day 17. To 
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evaluate the value of informal caregiving, we multiplied the market wage rate of a 
home health aide ($21 per hour) by time spent receiving care.108 
   
5.3.4 Statistical Analysis 
We estimated separate regression models for each outcome of interest: 
out-of-pocket medical expenditures, out-of-pocket nursing home expenditures, 
and time spent receiving active care, supervision, or both. A two-part modeling 
approach was used for all analyses as more than 25% of individuals had zero 
expenditures or received zero hours of caregiving.109 First, we used logistic 
regression to estimate the probability of experiencing the outcome of interest 
(i.e., any out-of-pocket medical expenditures, any out-of-pocket nursing home 
expenditures, or any informal caregiving). Second, we estimated the continuous 
outcome of interest among those who experienced that outcome using a 
generalized linear model with a log-link and gamma distribution.109 
All models included main effects for cognition, function, and 
behavioral/psychological symptoms.  Based on a review of the literature, we 
identified potential confounding variables. The two-part model evaluating out-of-
pocket medical expenditures controlled for age, gender, race, marital status, 
Medicaid status, supplemental insurance, household income, number of children, 
and an indicator for the total number of chronic conditions (0–8) among the 
following: stroke, diabetes, heart problems, hypertension, lung disease, cancer, 
psychiatric problems, or arthritis. The model also included terms for if an 
individual had a proxy respondent, and time between the ADAMS and HRS 
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assessments.  In a sensitivity analysis, we excluded terms for insurance status to 
evaluate their potential confounding effect on the relationship between clinical 
features and out-of-pocket spending. 
Due to small samples sizes, the second part of the two-part models 
evaluating out-of-pocket nursing home expenditures (>$0 n=45) and time 
caregiving (>0 hours caregiving n=91) did not include all potential confounders.  
Rather, based on theoretical and empirical considerations, we a-priori identified 
confounders that we believed were most strongly associated with the clinical 
features and outcome.  For the nursing home analysis, we included indicators for 
Medicaid and long-term care insurance status. For the time caregiving analysis, 
we included predictors for age, Medicaid status, number of chronic conditions, 
relationship between the caregiver and person with dementia (spouse, child, or 
other), and an indicator for whether the caregiver lived with the person with 
dementia. In another sensitivity analysis, we evaluated the effect of adding an 
additional covariate on the average marginal effects of the clinical features. The 
first part of the models had sample sizes sufficient to include all potential 
confounders. Finally, for the nursing home analysis, we conducted a similar 
sensitivity analysis (described above) where we excluded terms for insurance 
status.  
All analyses were conducted using ADAMS survey weights and Stata 
version 12 survey commands (Stata, College Station, TX). 
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5.4 Results 
5.4.1 Sample Characteristics  
Of individuals with dementia that met inclusion criteria for out-of-pocket 
expenditure analyses (n=215), the mean age was 83.42 years (SD 10.16); 
35.13% were male, and 80.43% were white (Table 5.6.1; Table A5.2 compares 
those included/excluded in the expenditure analysis).  A subsample of 
individuals with dementia resided in the community and had a caregiver 
informant provide information on time caregiving (n=131). The mean age of 
individuals with dementia in the time caregiving analyses was 83.36 years (SD 
10.42); 40.12% were male, and 26.88% were cared for by a spouse (Table 5.6.1; 
Table A5.3 compares those included/excluded in the time caregiving 
analysis).  
 
5.4.2 Out-of-Pocket Medical Expenditures 
The average (obtained from regressions) probability of having any out-of-
pocket medical spending (n=215) was 0.77 (95% CI: 0.67, 0.88) with average 
spending among those with these expenditures (n=155) of $252.23 (95% CI: 
$195.50, $308.97) per month.   
Cognition, function, and number of behavioral/psychological symptoms did 
not significantly predict if a person with dementia had out-of-pocket medical 
expenditures (Table 5.6.2).  However, not being on Medicaid, non-whites, and 
having comorbidities were associated with a higher probability of having 
expenditures (Table A5.5 reports complete results of the two-part model).  
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In the second part of the model, cognition and function significantly 
predicted the amount of out-of-pocket medical expenditures (Table 5.6.2). A one-
unit improvement in cognition was associated with $8.90 (95% CI: $1.18, $16.62) 
additional spending per month.  Conversely, one-additional functional limitation 
was associated with $24.68 (95% CI: $1.11, $48.25) additional spending per 
month. More household income also was significantly associated with spending 
(Table A5.5). The inclusion/exclusion of the insurance covariates did not alter 
effects of the clinical features on spending. 
 
5.4.3 Nursing Home Expenditures 
The average probability of having any out-of-pocket nursing home 
spending (n=215) was 0.26 (95% CI: 0.15, 0.37), with average spending for 
those with these expenditures (n=43) being $2,494.40 (95% CI: $863.20, 
$4,126.17) per month. 
One-additional functional limitation was associated with a 0.05 (95% CI: 
0.01, 0.09) increase in the probability of having out-of-pocket nursing home 
expenditures in a month. Neither cognition nor number of 
behavioral/psychological symptoms significantly predicted the probability of 
having nursing home expenditures; however, being white and not being married 
increased the risk of having expenditures (Table 5.6.2; Table A5.6 reports 
complete results of the two-part model). Among those with nursing home 
expenditures, no clinical feature predicted the amount. Being on Medicaid and 
having long-term care insurance were associated with less out-of-pocket 
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spending. In the sensitivity analysis, the inclusion of additional confounders, and 
the inclusion/exclusion of insurance covariates did not alter effects of the clinical 
features on spending. 
 
5.4.4 Time Spent Caregiving 
On average, the probability of receiving informal caregiving was 0.50 (95% 
CI: 0.37, 0.63) for active care (n=129), 0.46 (95% CI: 0.32, 0.60) for supervision 
(n=124), and 0.52 (95% CI: 0.38, 0.66) for both (n=131). Average hours of 
informal caregiving received per month among those who received caregiving 
was 215.75 (95% CI: 169.51, 262.00) for active care (n=86), 228.06 (95% CI: 
174.74, 281.38) for supervision (n=80), and 286.37 (95% CI: 245.26, 327.48) for 
both (n=91).  
 Function and number of behavioral/psychological symptoms, but not 
cognition, were significantly associated with an increase in the probability of 
receiving all types of informal caregiving (Table 5.6.3; Tables A5.7, A5.8, and 
A5.9 report complete results of the two-part models).  Specifically, one-
additional functional limitation and one-additional behavioral/psychological 
symptoms were associated with a 0.07 (95% CI: 0.01, 0.12) and 0.05 (95% CI: 
0.00, 0.09) increase in the probability of receiving both types of care in a month, 
respectively. Function was the only clinical feature to significantly predict the 
amount of all types of caregiving. One-additional functional limitation was 
associated with 43.65 (95% CI: 18.19, 69.12) additional hours of receiving both 
types of care in a month (Table 5.6.3).  Based on the replacement cost ($21 per 
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hour) of purchasing similar care in the market, one-additional functional limitation 
equals $916.65 worth of additional care being provided by a family caregiver in a 
month. In the sensitivity analysis, the inclusion of confounders did not change 
model conclusions. 
 
5.5 Discussion 
This is the first study of its kind to use nationally representative data with a 
sample that has a clinical diagnosis to estimate the effect of three important 
clinical features of dementia – cognition, function, and behavioral/psychological 
symptoms – on out-of-pocket medical and nursing home expenditures and time 
caregiving. We found differential effects of these clinical features on type of cost 
incurred and time caregiving.  
Cognition, function, and behavioral/psychological symptoms did not 
predict if an individual incurred any out-of-pocket expenditure, but having 
comorbidities were associated with a greater risk of having expenditures. The 
presence of comorbidities may amplify the effect of clinical features on out-of-
pocket expenditures110,111 and speaks to the importance of identifying and 
managing comorbidities in individuals with dementia. Future studies with larger 
sample sizes are warranted to investigate the combined effect of comorbidities 
and clinical features on expenditures.   
Among those with any out-of-pocket expenditure, better cognition and 
poorer function, but not number of behavioral/psychological symptoms and 
comorbidities, predicted more spending. Others have similarly reported this 
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differential effect.16,83 With greater cognitive impairment, medical care may be 
less aggressive reflecting either advance care directives, or clinical judgment 
concerning the marginal value of aggressive care, especially in the context of 
limited interventions for treating cognitive decline.92 In contrast, functional 
limitations can be managed throughout the disease with formal caregiving such 
as home care.112 
Poorer function predicted having nursing home expenditures, but no 
clinical feature significantly predicted the amount of such expenditures.  While 
other studies show that cognition, function, and behavioral/psychological 
symptoms predict nursing home placement, this is the first study to our 
knowledge to evaluate their independent effect on actual out-of-pocket nursing 
home payments.5 In our analysis, the probability of experiencing nursing home 
expenditures represents the probability of being in and paying out-of-pocket for 
the stay in the past two years. This is different than the probability of being 
institutionalized at a given point in time. The clinical features may not have 
predicted the amount of nursing home expenditures because individuals in our 
sample had been living in a facility over a long period of time (>1 year) leading to 
possibly lack of variation in expenditures. We were unable to distinguish between 
out-of-pocket payments for sub-acute care and long-term nursing home stays. 
However, given the long duration of nursing home stays of this sample, and 
limited Medicare nursing home benefit, the observed out-of-pocket spending is 
most likely due to long-term stays. 
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Poorer function and a greater number of behavioral/psychological 
symptoms significantly increase the probability of receiving informal care. 
Additionally, function predicted the amount of informal care that was received.  
As some interventions have been shown to improve or maintain daily function 
and reduce occurrences of behavioral/psychological symptoms, they may also 
impact the need for informal care and the amount provided.95-97,113-117 With few 
exceptions trials have not evaluated the effect of interventions on time spent 
caregiving.118,119 Future cost-effectiveness studies can use the information in our 
analyses to connect the clinical benefits of interventions with associated 
reductions in time caregiving, and hence related costs.  
In our analyses, poorer function was a leading predictor of out-of-pocket 
expenditures suggesting that functional decline is an important target for 
interventions.96 Little is known about the effect of function on costs across other 
diseases and how it compares to individuals with dementia. A recent study by 
Zhang et al. found that community-dwelling adults >50 years old with three or 
more functional limitations incurred $48.54 more in out-of-pocket expenditures 
per month than those without limitations.120 Conversely, we found that one-
additional functional limitation resulted in $24.68 additional out-of-pocket medical 
spending. Three limitations would result in $74.04 of additional spending. Thus, 
the effect of a functional limitation in a person with dementia is likely greater than 
the same limitation in someone without dementia. 
Our objective was to evaluate the effect of each clinical feature on out-of-
pocket spending, but Medicare and Medicaid expenditures represent other 
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important components of the total cost of dementia care as well. While less is 
known about the effect of each key feature on Medicaid expenditures, others 
have found that functional limitations are associated with more Medicare 
spending.91 Future studies should continue to investigate the relationship 
between each clinical feature and Medicare and Medicaid expenditures to 
identify specific intervention targets for care planning and projecting care costs. 
Our study is not without limitations. We rely on reported data from 
individuals with dementia (47% of the sample had a proxy respondent during the 
core HRS survey from which out-of-pocket spending data were obtained) and 
consequently we may underestimate out-of-pocket spending. However, HRS has 
validated procedures to limit under reporting of spending.22 While our results 
provide a basis for understanding out-of-pocket nursing home expenditures and 
time caregiving, we were unable to control for all potential confounders due to 
small sample sizes. Nevertheless, in sensitivity analyses our results were robust 
to the inclusion of additional confounders and overall conclusions did not change. 
Due to missing data (Figure 5.7.1, Panel A and B) on outcomes of interest and 
key covariates, we were unable to use all ADAMS participants identified as 
having dementia. This may limit the generalizability of findings. Yet, comparisons 
between those included to those excluded in the out-of-pocket expenditure 
analyses revealed few statistically significant differences (Table A5.2). 
Compared to those with dementia excluded from the time receiving caregiving 
analyses, those with dementia included were slightly younger, more cognitively 
intact, and had fewer functional limitations. This is not surprising given the time 
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caregiving analyses were limited to those residing in the community. Finally, we 
used cross-sectional data and did not have information on total time living with 
dementia. This may limit our view of the long-term implications of costs of 
dementia care such that our figures are underestimations. 
In conclusion, poorer function is associated with more of out-of-pocket 
medical spending, an increase in the risk of having out-of-pocket nursing home 
expenditures, and an increase in the risk and amount of informal caregiving 
received. Better cognition predicted more out-of-pocket medical spending, but 
cognition did not predict any other outcome. A greater number of 
behavioral/psychological symptoms predicted an increase in the risk of receiving 
all types of caregiving. Thus, behavioral/psychological symptoms and function 
should be targeted by interventions. 
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5.6 Tables 
Table 5.6.1 Sample characteristics  
 Out-of-Pocket and 
Nursing Home 
Expenditures 
(n = 215) 
Informal 
Caregiving 
Sample 
(n = 131) 
Characteristics of Persons with Dementia* 
Mean cognition (SD), MMSE†  16.05 (10.54) 17.89 (9.96) 
Mean number of functional limitations 
(SD) ‡   
6.02 (3.49) 5.48 (3.61) 
Mean number of 
behavioral/psychological symptoms 
(SD)§ 
2.68 (3.78) 2.40 (3.88) 
Mean age (SD), y 83.42 (10.16) 83.36 (10.08) 
Male,  % 35.13 38.22 
Non-Caucasian, % 19.57 17.57 
Married, % 24.60 29.84 
Long-term care insurance, % 2.72 3.94 
Medicaid, % 27.31 23.00 
Supplemental Insurance (e.g., 
Medigap),% 
24.86 26.51 
Mean household income (SD), $, in 
thousands 
21.30 (32.24) 23.67 (34.34) 
Mean number of children (SD) 2.87 (4.47) 3.07 (3.70) 
Mean number of comorbidities (SD) 2.92 (2.28) 2.66 (2.13) 
HRS proxy respondent, %|| 47.69 35.27 
Mean months between ADAMS and 
HRS assessments (SD) 
7.42 (4.63) 7.57 (5.76) 
Caregiver Characteristics ¶ 
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Relationship   
Spouse, % 21.86 26.88 
Child, % 46.66 56.45 
Other, % 31.48 16.67 
Live with person with dementia, % 46.11 60.36 
MMSE = Mini-Mental State Examination 
*Aging Demographics and Memory Study sample weights were used. 
†MMSE is scored from 0-30 with lower scores indicating greater cognitive 
impairment  
‡Measure of function is based on a modified version of the Functional Activities 
Questionnaire and is scored from 0-10 with higher scores indicating greater 
functional impairment 
§Number of behavioral and psychological symptoms identified on 
Neuropsychiatric Inventory Questionnaire (NPI) and is scored from 0-12 with 
higher scores indicating more symptoms.  
|| Represents the proportion of the sample that had a proxy respondent during the 
core HRS survey. 
¶ The proportions in the expenditure sample may not sum to 1 due to missing 
data. The informal caregiving sample is a subsample of the expenditure sample 
and does not have missing caregiver characteristics. 
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Table 5.6.2 Two-part model results for average monthly out-of-pocket medical and nursing home expenditures 
 Out-of-Pocket Medical Expenditures 
(Part 1 n = 215; Part 2 n = 155) 
Out-of-Pocket Nursing Home Expenditures 
(Part 1 n = 215; Part 2 n = 43) 
 Coefficient 
(95% CI) 
Marginal Effect 
(95% CI) 
Coefficient 
(95% CI) 
Marginal Effect 
(95% CI) 
Part 1 (logistic regression): probability of having a positive expenditure  
Cognition  0.06 0.01 -0.08 -0.01 
 (-0.02 , 0.14) (-0.01 , 0.01) (-0.21 , 0.05) (-0.03 , 0.01) 
Function -0.04 0.00 0.36 0.05 
 (-0.39 , 0.31) (-0.04 , 0.03) (0.05 , 0.67) (0.01 , 0.09) 
Behavioral and 
Psychological 
Symptoms 
-0.22 -0.02 -0.11 -0.01 
(-0.47 , 0.03) (-0.05 , 0.00) (-0.31 , 0.09) (-0.04 , 0.01) 
Part 2 (generalized linear model log link and gamma distribution): expenditures conditional on positive 
expenditures 
Cognition  0.04 $8.90 -0.03 -$75.11 
 (0.01 , 0.06) ($1.18 , $16.62) (-0.11 , 0.05) (-$297.44 , $147.22) 
Function 0.10 $24.68 -0.13 -$336.60 
 (0.01 , 0.18) ($1.11 , $48.25) (-0.88 , 0.61) (-$2,329.57 , $1,656.36) 
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Behavioral and 
Psychological 
Symptoms  
0.02 $4.21 0.00 -$6.27 
(-0.06 , 0.09) (-$15.15 , $23.57) (-0.38 , 0.38) (-$953.41 , $940.87) 
Notes: Cognition is evaluated using the Mini-Mental State Examination (MMSE scored 0-30). Higher MMSE scores 
indicate greater cognitive abilities. Function (scored 0-10) is evaluated as the number of functional limitations. Higher 
functional scores indicate more limitations.  Behavioral and psychological symptoms are evaluated as the number of 
symptoms endorsed by caregivers as occurring using the 12 items of the Neuropsychiatric Inventory Questionnaire.  
Higher behavioral/psychological scores indicate more symptoms. Marginal effects in the first part (second part) represent 
the change in probability (out-of-pocket expenditures) given a change in a measure of clinical feature. Both parts of the 
out-of-pocket medical expenditure models adjusted for age, gender, race, marital status, Medicaid status, supplemental 
insurance, household income, number of children, number of comorbidities, if respondent had an HRS proxy, and time 
between the ADAMS and HRS assessment.  The first part of the out-of-pocket nursing home model adjusted for age, 
gender, race, marital status, Medicaid status, long-term care insurance, supplemental insurance, household income, 
number of children, number of comorbidities, if respondent had an HRS proxy, and time between the ADAMS and HRS 
assessment.  The second part of out-of-pocket nursing home model adjusted Medicaid status and long-term care 
insurance.  
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Table 5.6.3 Two-part model results for average monthly time spent caregiving 
 Time Providing Active Help 
(Part 1 n = 129; Part 2 n = 86) 
Time Providing Supervision 
(Part 1 n = 124; Part 2 n = 80) 
Time Providing Any Help 
(Part 1 n = 131; Part 2 n = 91) 
 Coefficient 
(95% CI) 
Marginal Effect 
(95% CI) 
Coefficient 
(95% CI) 
Marginal Effect 
(95% CI) 
Coefficient 
(95% CI) 
Marginal Effect 
(95% CI) 
Part 1 (logistic regression): probability of any time-spent caregiving  
Cognition  -0.02 0.00 -0.07 -0.01 -0.05 -0.01 
 (-0.20 , 0.16) (-0.03 , 0.02) (-0.25 , 0.12) (-0.03 , 0.02) (-0.23 , 0.14) (-0.03 , 0.02) 
Function 0.45 0.07 0.52 0.07 0.44 0.07 
 (0.03 , 0.87) (0.01 , 0.13) (0.12 , 0.91) (0.01 , 0.13) (0.03 , 0.84) (0.01 , 0.12) 
Behavioral and 
Psychological 
Symptoms  
0.37 0.05 0.34 0.05 0.30 0.05 
(0.15 , 0.60) (0.02 , 0.09) (0.01 , 0.66) (0.00 , 0.09) (0.03 , 0.57) (0.00 , 0.09) 
Part 2 (generalized linear model log link and gamma distribution): time caregiving conditional on any 
caregiving 
Cognition  -0.03 
(-0.08 , 0.01) 
-7.17 
(-16.81 , 2.48) 
-0.01 
(-0.06 , 0.04) 
-2.54 
(-13.32 , 8.24) 
-0.03 
(-0.08 , 0.01) 
-9.58 
(-22.58 , 3.05)  
Function 0.19 
(0.06 , 0.32) 
40.68 
(10.10 , 71.26) 
0.27 
(0.19 , 0.36) 
61.72 
(40.87 , 82.56) 
0.15 
(0.06 , 0.24) 
43.65 
(18.19 , 69.12)  
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Behavioral and 
Psychological 
Symptoms  
-0.02 
(-0.10 , 0.07) 
-3.68 
(-21.84 , 
14.48) 
-0.01 
(-0.10 , 0.08) 
-2.20 
(-23.16 , 18.75) 
0.01 
(-0.08 , 0.09) 
2.44 
(-22.18 , 
27.07) 
Notes: Cognition is evaluated using the Mini-Mental State Examination (MMSE scored 0-30). Higher MMSE scores 
indicate greater cognitive abilities. Function (scored 0-10) is evaluated as the number of functional limitations. Higher 
functional scores indicate more limitations.  Behavioral and psychological symptoms are evaluated as the number of 
symptoms endorsed by caregivers as occurring using the 12 items of the Neuropsychiatric Inventory Questionnaire. 
Higher behavioral/psychological scores indicate more symptoms.  Marginal effects in the first part (second part) represent 
the change in probability (number of hours caregiving) given a change in clinical feature. The first part of all time spent 
caregiving models adjusted for age, gender, race, Medicaid status, household income, number of children, number of 
comorbidities, caregiver relationship to person with dementia, and if the caregiver lives with the person with dementia. The 
second part of the models adjusted for age, Medicaid status, number of comorbidities, caregiver relationship to person 
with dementia, and if the caregiver lives with the person with dementia. 
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5.7 Figure ! Panel!A:!Out,of,Pocket!Expenditure!Analyses! ! Panel!B:!Time!Receiving!Caregiving!Analyses! ! !! ! ! ! ! ! ! !! 856! Aging!Demographics!and!Memory!Study!Participants!(Wave!A!Assessment)!
! 856! Aging!Demographics!and!Memory!Study!Participants!(Wave!A!Assessment)!
! !
! ! ! ! ! ! ! ! ! !! ! ! ! ! ! ! ! ! !
548! Excluded!with!Normal!Cognition! ! ! ! ! ! 548! Excluded!with!Normal!Cognition!! ! ! ! ! ! ! ! ! !! ! ! ! ! ! ! ! ! !! ! 308! Participants!with!Dementia! ! 308! Participants!with!Dementia! ! !! ! ! ! ! ! ! ! ! !! ! ! ! ! ! ! ! ! !
93! Excluded! ! ! ! ! ! 177!! Excluded!! 75! Missing!Data!on!Covariates! ! ! ! ! ! ! 130! Missing!Data!on!Covariates!! ! ! ! ! ! ! ! ! ! !! 18! Linked!to!HRS!2000!Wave! ! ! ! ! ! ! 47! Living!in!Facility!! ! ! ! ! ! ! ! ! !! ! ! ! ! ! ! ! !! ! 215! Included!in!Out,of,Pocket!and!Nursing!Home!Expenditure!Analyses! ! 131! Included!in!Time!Receiving!Caregiving!Analyses!! ! !! ! ! ! ! ! ! ! ! !!  
Figure 5.7.1 Participation cohort, Aging, Demographics, and Memory Study  
Figure 5.7.1 Legend: Among those in the out-of-pocket medical and nursing home expenditure analyses 155 and 43 
persons with dementia had expenditures >$0, respectively.  The time receiving caregiving analyses were limited to 
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community-dwelling persons with dementia that had a caregiver provide information on time caregiving. Sample size in 
Panel B is for those with data on time spent receiving active care and supervision combined (91 persons with dementia 
received >0 hours of active help and supervision combined).
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Chapter 6: Societal and Family Lifetime Cost of 
Dementia: Implications for Policy  
 87 
6.1 Overview   
BACKGROUND: The longitudinal effect of dementia on costs to families, 
Medicaid, and Medicare is unknown. We estimated the lifetime and annual cost 
of dementia and the extra cost of caring for someone with dementia compared to 
someone without dementia. 
METHODS: We developed an evidence-based mathematical model to simulate 
disease progression for newly diagnosed individuals with dementia. Data driven 
trajectories of cognition, function, and behavioral/psychological symptoms were 
used to model disease severity and predict costs. Counterfactual analyses were 
conducted to evaluate costs between those who did and did not exhibit clinical 
features (net cost) and to evaluate the effect of reducing functional decline or 
behavioral/psychological symptoms by 10% for 12 months (implemented when 
Mini-Mental State Examination≤21).  
RESULTS: From time of diagnosis (mean age of 83 years and 60 month life 
expectancy) discounted total lifetime cost of care for a person with dementia was 
$322,900 (2015 dollars). Families incurred 72% of the total cost burden 
($144,160 in value of informal caregiving and $88,780 in out-of-pocket 
payments). Medicaid accounted for 12% ($37,390) and Medicare accounted for 
16% ($52,540) of total cost, respectively. Costs for a person with dementia over 
a lifetime were $194,890 greater (85% incurred by families) than for someone 
without dementia. Compared to natural disease progression, reducing functional 
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decline or behavioral/psychological symptoms by 10% resulted in $4,020 and 
$720 lower lifetime costs, respectively.     
CONCLUSIONS: Dementia substantially increases the lifetime costs of care. 
Long lasting effective interventions are needed to support families as they incur 
the most dementia cost. 
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6.2 Introduction 
More than 5 million Americans live with dementia.1 As the population 
ages, this number will increase placing an even greater burden on families, the 
long-term care system, and the economy.1 The societal economic burden of 
dementia consists of different types of costs (value of informal care, out-of-pocket 
expenditures, Medicaid long-term care expenditures, and Medicare 
expenditures), and several payers (family, Medicaid, and Medicare) bear various 
amounts of the economic responsibility. To facilitate planning at the family, state, 
and federal levels policymakers must better understand who incurs dementia 
costs over the life course of the disease.121  
Two recent studies highlight the economic burden of the disease over 
short periods of time. One found that in the last five years of life, a person with 
dementia receives more than $250,000 worth of care.18 The other found that 
those with dementia receive more than $56,000 in additional care in any given 
year compared to those without dementia.17 In both studies, families incurred the 
greatest cost burden due to informal caregiving and out-of-pocket payments for 
formal long-term care services. However, neither study accounted for the 
dynamic processes and substantial variations that occur in symptom presentation 
(cognitive and functional decline and behavioral/psychological symptoms of 
dementia) over the course of dementia. 
We estimated the total lifetime and annual costs of dementia care and the 
extra cost of caring for someone with dementia compared to someone without 
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dementia (net cost) using a comprehensive US dementia microsimulation model. 
Our model overcomes the limitations of previous dementia models by 
synthesizing data from a clinical registry, a nationally representative survey, and 
CMS Medicare data to model cognitive, functional, and behavioral/psychological 
trajectories and associated resource utilization.  
 
6.3 Methods 
6.3.1 Model Design 
Our evidence-based individual-level model simulated a newly diagnosed 
dementia patient’s disease progression (cognition, function, and 
behavioral/psychological symptoms), place of residence (community or long-term 
care facility), and Medicaid status (i.e., dual enrollment), in order to estimate 
lifetime and the full range of annual costs of care.  
Specifically, an individual entered the model as a community-dwelling 
incident case (Figure 6.7.1). At the point of entry (i.e., diagnosis of dementia), 
and prior to disease progression, the person with dementia’s personal 
characteristics (e.g., age, gender, race) and the characteristics of a primary 
caregiver were randomly generated from published incident statistics or derived 
from observational data (data sources described below; Table A6.1 details the 
baseline characteristics).89,122 This allowed the simulated population to be as 
representative as possible of the general population. As described in detail 
below, when the person with dementia aged (i.e., progressed through the model 
in monthly increments), their cognition, function, and behavioral/psychological 
 91 
symptoms (i.e., clinical features) changed and they could experience transitions 
between places of residence (community and long-term care facility), transitions 
from Medicare-only to dual enrollment, and death due to dementia or other 
causes.123-126 Personal characteristics, the clinical features, place of residence, 
and insurance status, were used to predict cost of care.  
 
6.3.2 Measures of Disease Progression: Cognition, Function, and 
Behavioral/Psychological Symptoms 
Dementia progression was modeled using three key clinical features -
cognition, function, and behavioral/psychological symptoms.61 Cognition was 
modeled using the Mini-Mental State Examination, which is scored from 0-30 
with lower scores indicating greater cognitive impairment.70 Function was 
modeled as the number of 10 functional limitations present and is scored from 0-
10 with higher scores indicating more limitations (Table A6.2). 
Behavioral/psychological symptoms were modeled as the number of 12 
symptoms present based on symptoms in the Neuropsychiatric Inventory 
Questionnaire Version Q (Table A6.3). These measures of the clinical features 
were chosen as they are consistent with the measures available in the data used 
to predict clinical trajectories, transitions in place of residence, and cost 
(prediction equations described below).81,127,128 
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6.3.3 Modeling Disease Progression 
To model disease progression over time, we adapted previously 
developed cognitive, functional, and behavioral/psychological mixed effect 
regression trajectory models of incident dementia cases (Table 6.6.1).81 These 
models used longitudinal data from the Uniform Data Set (March 2015 data 
freeze) of the National Alzheimer’s Coordinating Center to estimate separate 
trajectories of the three clinical features over time.122 The National Alzheimer’s 
Coordinating Center combines data from 34 past and present Alzheimer’s 
Disease Centers (ADCs) into the Uniform Data Set. During annual assessments, 
trained ADC providers administered a standardized protocol that includes 
cognitive, functional, and behavioral/psychological assessments. The trajectory 
models included explanatory variables believed to be risk factors of disease 
onset and decline (Tables A6.4, A6.5, and A6.6 report model coefficients for 
each trajectory model).  
 
6.3.4 Transitions Between Place of Residence, Medicare-only to Dual 
Enrollment, and Death 
Risk of transitioning to a long-term care facility was modeled using the Uniform 
Data Set. These long-term care admissions were assumed to be independent of 
Medicare-covered skilled nursing admissions as our estimates of Medicare 
expenditures (described below) included those for skilled nursing care. This 
assumption is supported by the few observed transitions in the data of individuals 
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moving from the facility back to the community indicating that most of the long-
term care admissions were likely for non-Medicare covered care. To model long-
term care admissions, we developed a parametric survival model to enable 
extrapolation beyond the available data and to predict the absolute risk of being 
institutionalized. We chose to use a Weibull survival model compared to an 
exponential or Gompertz models based on visual inspection of the hazard 
functions, and because the Weibull model had the lowest Akaike Information 
Criterion.129 Our long-term care facility risk model included lagged terms for the 
clinical features and potential confounders (Table 6.6.1; Table A6.7 reports 
Weibull model coefficients).  
Although individuals can transition from a long-term care facility to the 
community, as noted above few such transitions occurred in the Uniform Data 
Set. Therefore, we used published estimates of long-term care facility discharge 
rates to model transition back to the community (Table 6.6.1).130 
For persons with dementia not dually enrolled at disease onset, the risk of 
transitioning to Medicare-Medicaid varied by place of residence. Individuals in the 
community had a lower monthly risk (0.00206) of transitioning to Medicare-
Medicaid compared to those in a long-term care facility (0.01056)(Table 
6.6.1).131,132 Individuals with dementia who transitioned from a long-term care 
facility to the community continued to face an increased Medicare-Medicaid risk 
for six months.  
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Finally, mortality was modeled using background age-, sex-, and race- 
mortality rates obtained from US life tables.126 We then used a generalized 
reduced gradient method to calibrate age-, sex-, and race- specific hazard ratios 
to match published median dementia survival times based on age of disease 
onset (≤75, 76 – 80, 81 – 85, > 85).123,133 
 
6.3.5 Costs and Time Spent Caregiving 
We used published regression equations based on data from the Aging, 
Demographics, and Memory Study,89 a subsample of the Health and Retirement 
Study104 and linked to CMS Medicare data, to predict monthly hours spent 
receiving informal care, monthly out-of-pocket medical expenditures and monthly 
Medicare expenditures.127,128 Using the same data, we estimated a regression 
equation to predict monthly hours spent receiving formal community based 
caregiving (Table 6.6.1; Table A6.8 report model coefficient for formal 
community based caregiving). All the regression models included main effects 
for the clinical features (same measures used to model disease progression) and 
potential confounding variables.  
The value of informal and formal caregiving was estimated by multiplying 
monthly hours of caregiving by $21, which is equivalent to the national average 
cost of a home health aide.108 In our base-case, approximately 11 hours of 
informal caregiving a day ($21/hr) is equivalent to the daily private nursing home 
pay rate ($231/day)(Table 6.6.1). 
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 To model long-term care facility expenditures, we multiplied time spent in 
the facility by the daily pay rate taking into account differences in pay rate for 
private pay and Medicaid covered individuals (Table 6.6.1).108,134 Costs were 
discounted by 3% annually over an individual’s lifetime following a diagnosis of 
dementia and are reported in 2015 dollars. 
 
6.3.6 Statistical Analysis 
In the base-case analysis we simulated individual incident dementia cases 
to estimate mean lifetime and annual (conditional on surviving the entire year) 
total cost of care (value of informal care, Medicaid long-term care expenditures, 
Medicare expenditures, and individual out-of-pocket expenditures [medical care, 
long-term care, and formal care]), and the distribution of lifetime and annual cost 
by component.  
We conducted a counterfactual analysis to determine what would have 
happened to the same simulated person had they not experienced any cognitive 
deficits, functional limitations, behavioral/psychological symptoms, an excess 
Medicaid transition risk, or excess mortality due to dementia. We then compared 
expected costs between the simulated person with dementia and their 
counterfactual dementia free version (i.e., net cost). We also conducted a series 
of counterfactual analyses to determine the extra cost of caring for someone with 
dementia compared to individuals with 1, 3, and 5, functional limitations and no 
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cognitive deficits, no behavioral/psychological symptoms, and no excess 
Medicaid or morality risk due to dementia. 
Policymakers need a framework to be able to estimate the potential 
economic impact of policies/interventions that support individuals with 
dementia.121 To that end, we demonstrated the application of the model as a tool 
to evaluate the effects of interventions that can alter the trajectory of functional 
declines or behavioral/psychological symptoms. Specifically, we used the model 
to evaluate what would happen if an intervention were introduced that reduced 
functional decline by 10% or reduced the increase in number of 
behavioral/psychological symptoms by 10%. In this analysis, we assumed the 
hypothetical intervention was implemented during the early stage of the disease 
(MMSE ≤21) and that treatment effects lasted for 12 months. After 12 months 
individuals experienced the same trajectories as those in the base-case. 
Sub-analyses were performed to determine outcomes by age of dementia 
onset (75 and 90). There are computational challenges with evaluating 
uncertainty in microsimulation models.135,136 Therefore, to assess the effect of 
uncertainty on the total and net cost of dementia we evaluated outcomes when 
select parameters were set to their best/worst case (Table A6.9 details 
parameters varied in best/worst case sensitivity analysis). 
  The model was programed in TreeAge Pro 2016 and a deterministic 
version of the model was validated in Microsoft Excel 2011. Output from the 
model was analyzed in Stata version 12.  
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6.4 Results 
From the time of diagnosis (base-case mean age 83 years and life 
expectancy 60 months; Figure A6.10 reports distribution of survival time by 
place of residence and insurance status), mean discounted lifetime total value 
of care was $322,900 per person with dementia (Figure 6.7.2 Panel 1). Families 
incurred 72% of the total cost burden ($144,160 in the value of informal care and 
$88,780 in cash out-of-pocket payments). Medicaid payments ($37,390) 
accounted for 12% of total cost and Medicare payments ($52,540) accounted for 
16% of total cost. The annual total cost of dementia was not constant and 
peaked at six years ($90,920) post dementia onset (Figure A6.11). 
In counterfactual analysis, someone without dementia incurred $128,000 
in expenditures. Thus, an individual with dementia experienced $194,890 more 
cost over a lifetime than someone without dementia (Figure 6.7.2 Panel 1). 
Families shouldered the largest net cost burden (85% of net cost incurred by all 
parties) due to excess informal caregiving ($141,540 more caregiving received) 
and out-of-pocket payments ($24,150 more out-of-pocket spending). Medicaid 
($9,300) and Medicare ($19,890) payments accounted for 5% and 10% of net 
dementia cost, respectively. The annual net cost of dementia peaked in the fifth 
year post dementia onset (compared to the sixth year for total annual cost) at 
$74,960 (Figure 6.7.2 Panel 2). Compared to individuals with 1, 3, and 5, 
functional limitations (but no cognitive limitations or behavioral/psychological 
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symptoms) an individual with dementia received $179,030, $139,970, and 
$79,090 more care over a lifetime, respectively (Table A6.12). 
Finally, a hypothetical intervention (implemented when MMSE ≤21 and 
with a 12 month treatment effect) that reduced the rate of functional decline by 
10% resulted in $4,020 less lifetime cost than someone who received usual 
dementia care (Table A6.12). An intervention that reduced the number of 
behavioral/psychological symptoms by 10% resulted in $720 less lifetime cost. 
In sub-analyses, the mean total (net) value of care for a 75-year-old 
incident case was $530,220 ($281,480).  A 90-year-old dementia incident case 
incurred $249,360 (net $189,730) worth of care. Finally, in sensitivity analyses 
the total (net) cost of dementia in the best and worst case was $258,060 
($158,180) and $405,740 ($163,360), respectively (Figure A6.13).  
 
6.5 Discussion 
The economic burden of Alzheimer’s disease and related dementias and 
who pays such costs over the course of these conditions are of great policy 
relevance but cannot be directly estimated from existing data. This study 
presents a novel dementia policy model that syntheses data from a clinical 
registry, a nationally representative survey, and CMS Medicare data to model 
dementia clinical features, living arrangements, and insurance status over the life 
expectancy of an individual with dementia to inform policymakers of dementia 
cost. We found that total and net cost of dementia over a lifetime of dementia 
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(mean age of dementia onset 83 years with life expectancy of 60 months) was 
$322,900 and $194,890, respectively.  
 Our evaluation of the annual net cost of dementia revealed that total cost 
increased for the first five years post onset and then began to slowly decrease. 
At the same time, out-of-pocket and Medicaid expenditures increased with time. 
This pattern is attributable to several dynamic processes. In the early years 
following dementia onset, individuals in our model resided in the community. 
During this period, the amount of informal caregiving increased leading to greater 
cost. Eventually, individuals in the model began entering long-term care facilities. 
This resulted in an increase in net out-of-pocket and Medicaid expenditures, but 
on average this increase was less than the value of the substituted informal care 
(11 hours of informal care valued at $21/hr is equivalent to daily nursing home 
private pay rate of $231). Simultaneously, costs in the dementia free 
(counterfactual) individuals were increasing over time. The shift in locus of care 
combined with increasing cost in the counterfactual resulted in reduced 
cumulative net expenditures.  
 Our results highlight how the financial burden of dementia varies based on 
the payer. How/who pays for cost over time change from being attributable to 
informal care to out-of-pocket and Medicaid long-term care facility payments. At 
all times families incur the largest financial burden highlighting the importance 
and value of informal caregiving for individuals with dementia.3,137 From a 
government budgetary perspective informal caregiving is often viewed as a free 
 100 
or low-cost source of care. Yet, there are potentially unintended long-term 
consequences for caregivers associated with providing informal care (e.g., loss 
of retirement benefits and long-term health consequences).138 Moreover, due to a 
number of demographic trends the potential number of family caregivers 
available to provide such care to persons with dementia may decrease 
considerably in the upcoming decades.3,137  
There is continued enthusiasm from policymakers to implement policies 
and interventions that reduce long-term care facility admissions and length of 
stay.139-141 With reductions in long-term care facility utilization (and perhaps 
acute/rehabilitative care as well), informal caregivers will be relied upon to 
shoulder even more care. If policymakers are going to continue to rely on 
informal caregivers, then they should provide them with effective and proven 
support.3 Effective long-term care policy should reduce ineffective or wasteful 
care and promote high quality care (e.g., family-centered models that include rich 
sources of community-based support). Sometimes high quality care costs more, 
but as the results here suggest, such costs largely rely on the perspective of the 
payer. 
A review of model inputs indicates that potential reductions in all costs can 
be generated from proven interventions that effectively alter functional and 
behavioral/psychological trajectories, but the magnitude of savings will depend 
on effect sizes and their duration.96,116,117,142 Our evaluation of hypothetical 
treatments found that reducing the rate of functional decline (implemented when 
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MMSE ≤21) or number of behavioral/psychological symptoms by 10% for 12 
months reduced lifetime costs by $4,020 and $720, respectively. These savings 
are small relative to the total disease burden, but they still may represent 
important savings depending on the perspective of the payer.  
Although we approach the modeling of dementia cost differently, we 
derive similar estimates to others in the literature for annual net cost supporting 
the validity of our model.17,18,37 For example, from the second to tenth year, 
annual net costs in our model fall within the confidence interval of the net cross-
sectional cost of dementia reported by the RAND study (values in RAND analysis 
updated from 2010 to 2015 dollars for comparison with our results $64,750 95% 
CI: $49,170, $80,330).17 We extend results from prior studies by modeling 
disease progression from incidence to death to accurately account for the 
accumulation of outcomes over the entire course of the disease.10-12,143 Most 
importantly, our dementia policy model serves as a flexible tool to evaluate 
treatments and their effects on policy-relevant outcomes that are not normally 
captured in randomized trials (e.g., long-term care facility admission).  
 Our study has several limitations. Due to limited data, our estimates of the 
cost of dementia do not consider lost productivity of informal caregivers or the 
long-term health consequences of caregiving. If a caregiver had to stop working 
to take care of a person with dementia, the opportunity cost of giving up a job 
might be greater than the value we assigned to informal care ($21/hr). Due to 
limited data, our estimate of Medicaid expenditures is for long-term care facilities 
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and may underestimate total Medicaid spending. Our simulation model uses 
several risk equations each with a number of parameters. If parameters are 
incorrectly specified in the original risk equations then our predicted values may 
be biased.  At times the simulation model may extrapolate beyond the original 
data and this may result in unrepresentative predictive values. Despite these 
potential limitations, our results of annual net cost from the second to tenth year 
match those of the RAND study. 
In conclusion, individuals with dementia receive $322,900 worth of total 
care over the course of the disease, which equates to $194,890 more than if they 
did not have dementia. The vast majority of the total and net costs are borne by 
families for informal care and out-of-pocket payments. Policy and services should 
be implemented to support family members in the community. 
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6.6 Tables 
Table 6.6.1 Model inputs 
Model Estimate Monthly Point Estimate  Source 
Disease Progression    
Cognition, MMSE 
 
ƒ(timet, timet2, incident aget, incident aget * timet, gendert, educationt, 
racet, marital statust, regiont, regiont * timet, place of residencet-1, 
hypertensiont, hypertensiont * timet, diabetest, congestive heart 
failuret, congestive heart failuret * timet, stroket, 
hypercholesterolemiat, psychiatric problemst) 
81,144 
Function, number of functional 
limitations 
 
ƒ(timet, timet2, mmset, mmset * timet, incident aget, gendert, educationt, 
educationt * timet, racet, marital statust + regiont, place of residencet-
1, place of residencet-1 * timet, informant relationshipt, diabetest, 
diabetest * timet, congestive heart failuret, stroket, 
hypercholesterolemiat, psychiatric problemst) 
81,144 
Behavioral and psychological 
symptoms, number of symptoms 
 
ƒ(timet, timet2,  mmset, mmset * timet, incident aget, gendert, gendert * 
timet , educationt, racet, marital statust, regiont, place of residencet-1, 
informant relationshipt, informant relationshipt  * timet, hypertensiont,  
diabetest, congestive heart failuret, stroket, stroket * timet, 
81,144 
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hypercholesterolemiat, psychiatric problemst) 
Transitions    
Community to long-term care facility1 
 
ƒ(mmset-1, functiont-1, behavioral/psychological symptomst-1, live with 
someonet , gendert , educationt, racet, regiont, hypertensiont, 
diabetest, congestive heart failuret, stroket, hypercholesterolemiat, 
psychiatric problemst)  
144 
Probability of long-term care facility to 
community2  
  
0 – 90 days 0.13 130 
90 – 180 days 0.009 130 
180 – 365 days 0.003 130 
Probability of Medicare-Medicaid   
Community-dwelling3 0.00206 131,132 
Residing in long-term care facility 0.01056 131 
Time Spent Caregiving and 
Expenditures 
  
Time receiving informal caregiving4 ƒ(MMSEt, functiont, behavioral/psychological symptomst, aget, 
Medicaidt, number of comorbiditiest, caregiver relationshipt, caregiver 
live with the person with dementiat) 
127 
 105 
Medicare expenditures ƒ(MMSEt, functiont, behavioral/psychological symptomst, aget, gendert, 
racet, martial statust, number of comorbiditiest) 
128 
Out-of-pocket medical expenditures5  ƒ(MMSEt, functiont, behavioral/psychological symptomst, aget, gendert, 
racet, martial statust, Medicaidt, supplemental insurancet, household 
incomet, number of childrent, number of comorbiditiest, proxy 
respondentt, time between ADAMS and HRS assessmentt) 
127 
Time receiving formal caregiving6 ƒ(MMSEt, functiont, behavioral/psychological symptomst) 89 
Monthly private nursing home 
expenditures 
$7,270 108 
Monthly Medicaid nursing home 
expenditures 
$6,236 108,134   
Abbreviations: MMSE = Mini-Mental State Examination 
1Models the risk of long-term care facility admissions excluding admissions for Medicare covered skilled nursing care.  
2If a person with dementia did not leave the long-term care facility within a year it was assumed they remain in the facility 
for life.  
3Once an individual was dual-eligible it was assumed they would enroll in Medicaid and remain on Medicaid for life. 
Background Medicaid transition risk for community-dwelling individuals without dementia was 0.0008.  Individuals with 
 106 
dementia had an excess transition risk (hazard ratio 2.575).  All individuals residing in a facility had a 0.0085 added 
Medicaid transition risk.  
4Time receiving informal caregiving was modeled with a two-part model. In the first part, a logistic regression was used to 
estimate if a person received caregiving. In the second part of the model a log-link gamma distribution model was used to 
estimate the amount of caregiving received. The first part of the model included additional terms for gender, race, 
supplemental insurance, household income, and number of children. Value of informal caregiving was $21/hour. 
5Out-of-pocket medical expenditures were modeled with a two-part model. In the first part, a logistic regression was used 
to estimate if a person had any out-of-pocket expenditures. In the second part, a log-link gamma distribution model was 
used to estimate the amount of out-of-pocket expenditures. 
6Value of formal caregiving was modeled with a two-part model. In the first part, a logistic regression was used to estimate 
if a person received any formal caregiving. In the second part, a log-link gamma distribution model was used to estimate 
the amount of out-of-pocket expenditures. Due to small sample size the second part only included main effects for the 
clinical features. The first part of the model included additional terms for age, gender, race, Medicaid status, household 
income, number of children, number of comorbidities, and if the caregiver lives with the person with dementia. Value of 
formal caregiving was $21/hour. 
 107 
6.7 Figures 
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Figure 6.7.1 Dementia policy model structure  
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Figure 6.7.1 Legend: Persons with dementia are individually simulated. At point of entry (i.e., diagnosis) personal 
characteristics are generated. During each monthly cycle an individual’s cognitive and functional abilities and number of 
behavioral and psychological symptoms are determined. The clinical features and personal characteristics are used to 
determine transitions between the community and long-term care facility. Place of residence informs risk of transiting to 
Medicaid. Personal characteristics, the clinical features, place of residence, and insurance status, were used to estimate 
cost of care. 
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Figure 6.7.2 Distribution of expected total and annual cost 
Figure 6.7.2 Legend: Panel 1: Discounted average total and net lifetime cost of dementia by cost type. The value of 
informal caregiving is $21/hour.  Out-of-pocket expenditures include those for medical care, long-term care facility, and 
formal caregiving. The length of the bar is equal to average lifetime expenditures. Net cost represents the difference in 
expenditures between dementia cases and counterfactual dementia free cases. Panel 2: Discounted average annual net 
cost of dementia by cost type for an 83-year-old incident case (base-case). Annual costs are calculated for those 
conditional on surviving the entire year.  
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Chapter 7: Summary  
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The purpose of our study was to inform policymakers as to how cost 
accumulate over the course of an individual’s dementia and who pays for such 
costs. To accomplish this, we constructed a novel dementia microsimulation 
model that synthesized data from the National Alzheimer’s Coordinating Center 
Uniform Data Set, the Aging, Demographics, and Memory Study (ADAMS), the 
Health and Retirement Study (HRS), CMS Medicare, and estimates from the 
literature.  
 In Chapter 3 (aim 1), we used data from the National Alzheimer’s 
Coordinating Center Uniform Data Set to evaluate cognitive, functional, and 
behavioral/psychological trajectories of newly diagnosed individuals with 
dementia.81 Key predictors of cognitive decline included age of dementia onset, 
geographic region of residence, and history of hypertension and congestive heart 
failure. Predictors of functional decline included place of residence in the 
previous observation and a history of diabetes. Finally, cognition was the only 
variable to explain changes in behavioral/psychological symptoms. 
Independently, this chapter provides insight into potential sociodemographic and 
clinical factors that may be associated with accelerated/decelerated decline in 
the clinical features of dementia. Results from this portion of the analysis were 
used in the dementia simulation model to predict declines in cognition, function, 
and behavioral/psychological symptoms.  
In Chapter 4 (aim 2), we used data from ADAMS, part of the HRS, linked 
to CMS Medicare data to evaluate the independent contributions of cognition, 
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function, and behavioral/psychological symptoms to Medicare expenditures and 
Medicare utilization.128 Poorer function, but not cognition or 
behavioral/psychological symptoms, was associated with more Medicare 
spending. The effect of function on Medicare expenditures was driven, in part, 
through the effect of poorer function on more hospitalizations and skilled nursing 
care. Interventions that seek to maintain or improve function could reduce 
Medicare expenditures for individuals with dementia. Results from this portion of 
the analysis were used in the dementia simulation model to predict Medicare 
expenditures associated with cognition, function, and behavioral/psychological 
symptoms.  
In Chapter 5 (aim 2), we used ADAMS data to evaluate the independent 
contributions of cognition, function, and behavioral/psychological symptoms to 
out-of-pocket medical expenditures and time caregiving.127 No clinical feature 
predicted if an individual had any out-of-pocket medical expenditure, but among 
those with out-of-pocket expenditures higher cognition and poorer function were 
associated with more spending. Poorer function and more 
behavioral/psychological symptoms were associated with a greater risk of 
receiving informal caregiving, and poorer function also was associated with more 
informal caregiving. Interventions that maintain or improve function could result in 
large savings to families. Results from this portion of the analysis were used in 
the dementia simulation model to predict out-of-pocket expenditures and time 
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caregiving associated with cognition, function, and behavioral/psychological 
symptoms.  
 In Chapter 6 (aim 3), the trajectory (Chapter 3) and cost (Chapters 4 and 
5) estimates were incorporated as inputs in a US dementia simulation model that 
simulated a newly diagnosed dementia patients’ disease progression and 
associated cost. Clinical trajectories were also used to inform transitions between 
places of residence (community or long-term care facility) that in turn informed 
transitions in insurance status (Medicare-only or dual enrollment). Mean life 
expectancy for a newly diagnosed dementia case (base case mean age of 
diagnosis 83 years) was 70 months. The average lifetime cost of care was 
$322,900. Families incurred 73% of the total cost burden ($144,160 for informal 
caregiving and $88,780 in out-of-pocket payments). Costs for a person with 
dementia were $194,890 more over a lifetime than for someone without dementia 
(85% of net cost incurred by families).  
In summary, families bare the largest financial burden associated with 
dementia. Family financial obligations are predominately due to informal 
caregiving and out-of-pocket payments for long-term care services. As 
policymakers continue to rely on informal family caregivers to provide a majority 
of dementia care, they must also provide them with effective and proven support. 
Potentially large reductions in costs to all payers can be achieved by managing 
functional declines and behavioral symptoms. Several nondrug interventions 
have been shown to effectively control functional decline and behavioral 
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symptoms. However, the effects of these interventions on policy relevant 
economic outcomes (e.g., time caregiving) are unknown. Future studies can use 
our US dementia simulation model as a tool to evaluate the economic effects of 
interventions that address cognitive, functional, and behavioral symptoms of 
dementia.  
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Figure A3.1 Participation cohort 
Figure A3.1 Legend: The National Alzheimer’s Coordinating Center provided 
the investigators with data from the Uniform Data Set (March 2015 Freeze) that 
met the following criteria: individuals >70 years old with a clinical diagnosis of 
probable Alzheimer’s Disease or dementia; or a Clinical Dementia Rating Scale 
Score >0 or Mini-Mental State Exam Score ≤ 25. Using this data file we applied 
the study inclusion criteria to obtain the analysis sample. 
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Equation A3.2 Simple trajectory model equation:  
Yij = b0 + b1Timeij + b2Time2ij +z1j + z2jTimeij + z3jTime2ij +uij  
Notes: Yij (i indexes individuals and j indexes time) represents the outcome of 
interested (i.e., cognition, function, or behavior).  z1j represents a random 
intercept, z2jTimeij and z3jTime2ij represent random slopes, and uij represents and 
individuals specific error term.  
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Table A3.3 Baseline sample characteristics of non-dropouts and dropouts 
 Dropouts and Non-Dropouts 
(n = 553) 
Non-Dropouts*  
(n = 457) 
Dropouts 
(n = 96)† 
P-value‡ 
Age in Years at Diagnosis, M (SD) 79.59 (6.19) 79.91 (6.26) 78.07 (5.70) 0.008 
Male, N (%) 293 (53) 251 (55) 42 (44) 0.042 
Years of Education, M (SD) 15.39 (3.02) 15.37 (2.91) 15.48 (3.52) 0.752 
Race    0.384 
Caucasian, N (%) 476 (86) 396 (87) 80 (84)  
African American, N (%) 47 (9) 39 (8) 8 (8)  
Other, N (%) 30 (5) 22 (5) 8 (8)  
Marital Status at Diagnosis    0.251 
Married, N (%) 392 (71) 327 (71) 65 (68)  
Widowed, N (%) 120 (22) 100 (22) 20 (21)  
Other, N (%) 41 (7) 30 (7) 11 (11)  
Region of Residence    0.001 
Northeast, N (%) 129 (23) 85 (19) 44 (46)  
South, N (%) 36 (7) 28 (6) 8 (8)  
West, N (%) 138 (25) 120 (26) 18 (19)  
Midwest, N (%) 56 (10) 51 (11) 5 (5)  
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Not Specified, N (%) 194 (35) 173 (38) 21 (22)  
Place of Residence at Diagnosis    0.777 
Community Dwelling, N (%) 533 (96) 440 (96) 93 (97)  
Facility, N (%) 20 (4) 17 (4) 3 (3)  
Informant Relationship     0.719 
Spouse, N (%) 349 (63) 291 (64) 58 (60)  
Other Family Member, N (%)  157 (28) 129 (28) 28 (29)  
Other, N (%) 47 (9) 37 (8) 10 (11)  
Comorbidities      
Ever Hypertension, N (%) 373 (67) 311 (68) 62 (65) 0.510 
Ever Diabetes, N (%) 80 (14) 64 (14) 16 (17) 0.501 
Ever Congestive Heart Failure, N 
(%) 
34 (6) 29 (6) 5 (5) 0.673 
Ever Hypercholesterolemia, N (%) 382 (69) 316 (69) 66 (69) 0.939 
Ever Stroke, N (%) 58 (10) 47 (10) 11 (11) 0.733 
Ever Psychiatric Problems, N (%) 61 (11) 50 (11) 11 (11) 0.883 
MMSE at Diagnosis, M (SD)§ 24.38 (3.21) 24.22 (3.24) 25.03 (2.96) 0.028 
FAQ Score at Diagnosis, M (SD)|| 10.90 (7.10) 10.89 (7.12) 10.95 (7.04) 0.947 
NPI Total Score at Diagnosis, M 
(SD)¶ 
3.74 (3.85) 3.90 (3.99) 2.98 (3.07) 0.033 
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Clinical Dementia Rating Score    0.831 
None, N (%) 0 (0.00) 0 (0.00) 0 (0.00)  
Very Mild, N (%) 330 (59.67) 275 (60.18) 55 (57.29)  
Mild, N (%) 209 (37.79) 171 (37.42) 38 (39.58)  
Moderate, N (%) 14 (2.53) 11 (2.41) 3 (3.12)  
Severe, N (%) 0 (0.00) 0 (0.00) 0 (0.00)  
Number of Follow up Visits, M (SD) 4.08 (1.17) 4.13 (1.20) 3.88 (1.02) 0.055 
*Non-dropouts is the sample used for analyses in the main text 
†Dropouts consisted of individuals who requested not to participate in follow up assessments 
‡Comparison of non-dropouts and dropouts 
§MMSE = Mini-mental State Exam 
||FAQ = Functional Activities Questionnaire 
¶ NPI-Q = Neuropsychiatry Inventory Questionnaire
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Equation A3.4 Cognition trajectory model equation:  
Yij = b0 + b1Timeij + b2Time2ij + b3Age of Onsetij  + b4Age of Onsetij * Timeij  + 
b5Maleij  + b6Educationij  + b7Raceij  + b8Marital Statusij  + b9Region of 
Residenceij  + b10Region of Residenceij *  Timeij  + b11Place of Residenceij  + 
b12Hypertensionij  + b13Hypertensionij  * Time2ij + b14Diabetesij + b15Congestive 
Heart Failureij + b16Congestive Heart Failureij * Timeij  + b17Strokeij + 
b18Hypercholesterolemiaij + b19Psychiatric Problemsij  + z1j + z2jTimeij + z3jTime2ij 
+uij  
Notes: Yij (i indexes individuals and j indexes time) represents cognition.  z1j 
represents a random intercept, z2jTimeij and z3jTime2ij represent random slopes, 
and uij represents and individuals specific error term. 
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Table A3.5 Supplemental analyses of cognitive trajectories 
  Effects 
Parameter Estimates of 
Cognitive Trajectories: 
Standardized MMSE 
(n = 457) 
Parameter Estimates of 
Cognitive Trajectories 
Including Dropouts  
(n = 553) 
Intercept -1.201 20.603*** 
(-2.584, 0.181) (16.598, 24.608) 
Time -1.187*** -4.692*** 
 (-1.867, -0.508) (-6.719, -2.665) 
Time2 -0.036*** -0.111*** 
 
(-0.056, -0.015) (-0.172, -0.050) 
Age of Onset (Years) 0.000 0.002 
(-0.014, 0.015) (-0.041, 0.044) 
Age of Onset (Years) * Time 0.010* 0.038** 
(0.001, 0.018) (0.013, 0.063) 
Male  0.071 0.158 
(-0.113, 0.255) (-0.384, 0.699) 
Years of Education 0.073*** 
(0.044, 0.102) 
0.219*** 
(0.136, 0.302) 
Race (ref = White)   
African American -0.503** 
(-0.815, -0.191) 
-1.325** 
(-2.229, -0.421) 
Other -0.085 
(-0.481, 0.312) 
-0.487 
(-1.581, 0.607) 
Marital Status (ref = Widowed)   
Married -0.180 -0.690* 
(-0.383, 0.024) (-1.288, -0.093) 
Other -0.012 0.169 
(-0.330, 0.306) (-0.745, 1.082) 
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Region of Residence (ref = 
Northeast)   
South 0.008 0.286 
(-0.384, 0.399) (-0.802, 1.375) 
West -0.368** -1.016** 
(-0.622, -0.114) (-1.722, -0.310) 
Midwest 0.369* 1.173* 
(0.051, 0.688) (0.251, 2.095) 
Not Specified  -0.059 -0.225 
(-0.300, 0.181) (-0.883, 0.434) 
Region of Residence (ref = 
Northeast) * Time   
South  -0.109 -0.216 
(-0.342, 0.125) (-0.890, 0.459) 
West -0.229** -0.500* 
(-0.383, -0.076) (-0.938, -0.063) 
Midwest 0.025 0.279 
(-0.161, 0.212) (-0.276, 0.834) 
Not Specified  -0.087 -0.087 
(-0.229, 0.056) (-0.490, 0.317) 
Community-dwelling in Previous 
Time Period (ref = Facility) 
0.146 0.530 
(-0.121, 0.414) (-0.255, 1.315) 
Ever Hypertension 0.129 0.522 
(-0.060, 0.318) (-0.031, 1.074) 
Ever Hypertension * Time 0.114* 0.410* 
(0.007, 0.222) (0.087, 0.732) 
Ever Diabetes  -0.067 -0.661 
(-0.318, 0.184) (-1.386, 0.063) 
Ever Congestive Heart Failure  0.064 0.155 
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 (-0.285, 0.413) (-0.870, 1.180) 
Ever Congestive Heart Failure * 
Time 0.216* 0.699* 
 (0.010, 0.422) (0.070, 1.329) 
Ever Stroke -0.097 -0.488 
 (-0.353, 0.159) (-1.239, 0.262) 
Ever Hypercholesterolemia 0.077 0.288 
(-0.112, 0.266) (-0.266, 0.842) 
Ever Psychiatric Problems 0.245 0.690 
 (-0.026, 0.517) (-0.099, 1.479) 
Notes: MMSE = Mini-mental State Exam (scored 0–30). Higher scores indicate 
greater cognitive abilities.  
* p <0.05. ** p<0.01. *** p<0.001. 
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Equation A3.6 Function trajectory model equation  
Yij = b0 + b1Timeij + b2Time2ij +b3Cognitive Statusij + b4Cognitive Statusij * Timeij + 
b5Age of Onsetij + b6Maleij + b7Educationij + b8Educationij * Timeij + b9Raceij + 
b10Marital Statusij +  b11Region of Residenceij  + b12Place of Residenceij + 
b13Place of Residenceij * Timeij + b14Informant Relationshipij + b15Hypertensionij + 
b16Diabetesij + b17Diabetesij * Timeij  + b18Congestive Heart Failureij + b19Strokeij + 
b20Hypercholesterolemiaij + b21Psychiatric Problemsij + z1j + z2jTimeij + z3jTime2ij 
+uij  
Notes: Yij (i indexes individuals and j indexes time) represents function.  z1j 
represents a random intercept, z2jTimeij and z3jTime2ij represent random slopes, 
and uij represents and individuals specific error term. 
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Table A3.7 Supplemental analyses of functional trajectories 
Effects 
Parameter Estimates 
of Functional 
Trajectories: 
Standardized FAQ 
(n =457) 
Parameter Estimates of 
Functional Trajectories 
Including Dropouts  
(n = 553) 
Intercept 2.899*** 29.866*** 
 
(1.674 , 4.124) (22.025 , 37.707) 
Time 0.285** 1.930** 
 (0.081 , 0.489) (0.566 , 3.293) 
Time2 -0.039*** -0.278*** 
 
(-0.052 , -0.026) (-0.368 , -0.189) 
Cognitive Status (MMSE) -0.057*** -0.433*** 
 
(-0.073 , -0.041) (-0.541 , -0.325) 
Cognitive Status (MMSE) * 
Time 
-0.004 -0.021 
(-0.009 , 0.001) (-0.054 , 0.013) 
Age of Onset (Years) -0.002 -0.004 
 
(-0.014 , 0.010) (-0.081 , 0.073) 
Male -0.319*** -2.229*** 
 
(-0.474 , -0.165) (-3.229 , -1.230) 
Years of Education -0.017 -0.103 
 
(-0.045 , 0.011) (-0.278 , 0.072) 
Years of Education * Time 0.008 0.058* 
 (-0.001 , 0.016) (0.003 , 0.112) 
Race (ref = White)   
African American -0.494*** -3.744*** 
 (-0.748 , -0.240) (-5.365 , -2.124) 
Other -0.015 0.803 
 
(-0.337 , 0.307) (-1.149 , 2.755) 
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Marital Status (ref = 
Widowed)   
Married -0.165 -0.959 
 (-0.359 , 0.029) (-2.245 , 0.327) 
Other -0.046 -0.643 
 
(-0.302 , 0.211) (-2.300 , 1.014) 
Region of Residence (ref = 
Northeast)   
South -0.002 0.426 
 (-0.319 , 0.316) (-1.523 , 2.375) 
West 0.250* 2.032** 
 (0.043 , 0.457) (0.768 , 3.296) 
Midwest -0.312* -2.149* 
 (-0.568 , -0.056) (-3.786 , -0.511) 
Not Specified 0.007 0.552 
 (-0.187 , 0.200) (-0.618 , 1.722) 
Community-dwelling in 
Previous Time Period (ref = 
Facility) 
-0.635*** -3.824*** 
(-0.968 , -0.302) (-6.019 , -1.628) 
Community-dwelling in 
Previous Time Period (ref = 
Facility)* Time 
0.154** 0.882* 
(0.050 , 0.257) (0.190 , 1.575) 
Informant Relationship (ref = 
Spouse)   
Other Family Member -0.133 -0.760 
 (-0.310 , 0.045) (-1.948 , 0.428) 
Other -0.236 -1.126 
 (-0.483 , 0.012) (-2.791 , 0.539) 
Ever Hypertension 0.003 -0.206 
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 (-0.151 , 0.156) (-1.194 , 0.782) 
Ever Diabetes 0.148 1.088 
 (-0.089 , 0.386) (-0.422 , 2.597) 
Ever Diabetes * Time -0.075* -0.429 
(-0.149 , -0.001) (-0.923 , 0.066) 
Ever Congestive Heart 
Failure 0.043 -0.699 
 (-0.239 , 0.326) (-2.525 , 1.128) 
Ever Stroke 0.311** 2.241*** 
 (0.112 , 0.510) (0.940 , 3.542) 
Ever Hypercholesterolemia -0.180* -1.125* 
 (-0.334 , -0.025) (-2.122 , -0.128) 
Ever Psychiatric Problems -0.100 -0.594 
 (-0.321 , 0.122) (-2.011 , 0.822) 
Notes: FAQ = Functional Activities Questionnaire (scored 0 – 30). Higher scores 
indicate more functional limitations.  
* p <0.05. ** p<0.01. *** p<0.001. 
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Equation A3.8 Behavioral/psychological symptoms trajectory model equation  
Yij = b0 + b1Timeij + b2Time2ij +b3Cognitive Statusij + b4Cognitive Statusij * Timeij + 
b5Age of Onsetij + b6Maleij + b7Maleij * Timeij  + b8Educationij + b9Raceij + b10Marital 
Statusij + b11Region of Residenceij + b12Place of Residenceij + b13Informant 
Relationshipij + b14Informant Relationshipij * Timeij + b15Hypertensionij + 
b16Diabetesij + b17Congestive Heart Failureij + b18Strokeij  + b19Strokeij  * Timeij + 
b20Hypercholesterolemiaij + b21Psychiatric Problemsij +  z1j + z2jTimeij + z3jTime2ij 
+uij 
Notes: Yij (i indexes individuals and j indexes time) represents severity of 
behavioral/psychological symptoms.  z1j represents a random intercept, z2jTimeij 
and z3jTime2ij represent random slopes, and uij represents and individuals specific 
error term. 
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Table A3.9 Supplemental analyses of behavioral/psychological trajectories 
Effect 
Parameter 
Estimates of 
Behavioral 
Trajectories: 
Standardized NPI-Q 
(n =457) 
Parameter Estimates 
of Behavioral 
Trajectories Including 
Dropouts  
(n = 553) 
Intercept 1.678* 9.558*** 
 (0.367 , 2.988) (4.948 , 14.167) 
Time 0.315** 1.258*** 
 
(0.122 , 0.507) (0.544 , 1.972) 
Time2 0.000 -0.001 
 
(-0.017 , 0.018) (-0.069 , 0.066) 
Cognitive Status (MMSE)  -0.018 -0.062 
 (-0.037 , 0.001) (-0.131 , 0.007) 
Cognitive Status (MMSE) * Time -0.008* -0.030* 
 
(-0.014 , -0.001) (-0.054 , -0.007) 
Age of Onset (Years) -0.020** -0.066** 
 
(-0.034 , -0.007) (-0.112 , -0.019) 
Male  0.042 0.143 
 (-0.144 , 0.228) (-0.521 , 0.806) 
Male * Time -0.065 -0.222 
 (-0.141 , 0.012) (-0.500 , 0.055) 
Years of Education -0.011 -0.041 
 
(-0.038 , 0.015) (-0.132 , 0.050) 
Race (ref = White)   
African American -0.122 -0.572 
 (-0.401 , 0.158) (-1.554 , 0.410) 
Other -0.031 0.169 
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(-0.386 , 0.324) (-1.020 , 1.357) 
Marital Status (ref = Widowed)    
Married 0.025 -0.003 
 (-0.204 , 0.254) (-0.827 , 0.821) 
Other 0.237 0.554 
 
(-0.059 , 0.533) (-0.490 , 1.598) 
Region of Residence (ref = 
Northeast)   
South 0.445* 1.744** 
 (0.096 , 0.794) (0.568 , 2.920) 
West 0.195 0.634 
 (-0.033 , 0.422) (-0.131 , 1.400) 
Midwest 0.195 0.780 
 (-0.090 , 0.480) (-0.222 , 1.781) 
Not Specified 0.318** 1.114** 
 (0.104 , 0.532) (0.401 , 1.826) 
Community-dwelling in Previous 
Time Period (ref = Facility) 
0.212 0.515 
(-0.028 , 0.452) (-0.347 , 1.376) 
Informant Relationship (ref = 
Spouse)   
Other Family Member 0.028 0.065 
 (-0.203 , 0.259) (-0.774 , 0.904) 
Other -0.088 -0.583 
 (-0.433 , 0.257) (-1.826 , 0.661) 
Informant Relationship (ref = 
Spouse) * Time   
Other Family Member * Time -0.076 -0.335* 
 (-0.157 , 0.005) (-0.629 , -0.042) 
Other * Time -0.105 -0.358 
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 (-0.224 , 0.014) (-0.794 , 0.078) 
Ever Hypertension 0.185* 0.539 
 (0.016 , 0.354) (-0.061 , 1.139) 
Ever Diabetes 0.130 0.641 
 (-0.094 , 0.355) (-0.146 , 1.428) 
Ever Congestive Heart Failure 0.156 0.566 
 (-0.154 , 0.467) (-0.542 , 1.674) 
Ever Stroke 0.281 0.962 
 (-0.039 , 0.601) (-0.182 , 2.106) 
Ever Stroke * Time -0.129 -0.442 
 (-0.267 , 0.008) (-0.934 , 0.051) 
Ever Hypercholesterolemia -0.155 -0.579 
 (-0.323 , 0.014) (-1.180 , 0.023) 
Ever Psychiatric Problems 0.331** 1.395** 
 
(0.087 , 0.574) (0.536 , 2.253) 
Notes: NPI-Q = Neuropsychiatric Inventory Questionnaire severity score (scored 
0 – 36). Higher scores indicate more severe behavioral/psychological symptoms.  
* p <0.05. ** p<0.01. *** p<0.001.
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Table A4.1 Sample characteristics of individuals’ included/excluded from analysis 
Variable Respondents included in 
out-of- analysis (n = 234) 
Respondents with dementia 
excluded from analysis due to 
missing data (n = 74) 
P-value 
Mean cognition (SD), MMSE 16.06 (11.94) 15.67 (11.80) 0.855 
Mean number functional limitations (SD)  6.18 (3.71) 6.78 (4.14) 0.243 
Mean number of behavioral/psychological 
symptoms (SD) 
2.63 (4.23) 2.32 (3.25) 0.460 
Mean age (SD), y 84.12 (10.87) 84.36 (12.61) 0.889 
Male,  % 35.37 17.21 0.065 
Non-Caucasian, % 18.88 24.13 0.651 
Married, % 21.76 27.16 0.461 
Mean number of chronic conditions 2.96 (2.67) 2.81 (2.03) 0.518 
Notes. MMSE = Mini-Mental State Examination  
Continuous variables were compared using two-sided Students t-test and categorical variables were compared using chi-
square test.  Data for those excluded from analyses are presented for those with data available on the variable of interest.  
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 856 Aging Demographics and 
Memory Study Participants 
(Wave A Assessment) 
    
    
548 Excluded with 
Normal Cognition 
  
    
    
  308 Participants with Dementia 
    
    
74 Excluded   
 40 Missing Data on 
Covariates 
  
     
 3 Medicare Data 
Not Available 
  
     
 31 Not Continually 
Enrolled in Fee-
for-service 
Medicare 
  
    
    
  234 Included in Analyses 
    
Figure A4.2 Analysis sample from Aging, Demographics, and Memory Study	
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Figure A4.3 Marginal effects of clinical features on Medicare expenditures 
Figure A4.3 Legend. Dashed lines represent 95% confidence interval. Marginal effects represent the change in Medicare 
expenditures associated with a change (1 point decline in cognition, or 1 point increase in function and 
behavioral/psychological symptoms) from better to poorer for each clinical feature. Higher cognitive scores indicate 
greater cognitive abilities. Higher functional scores indicate more functional limitations. Higher behavioral/psychological 
scores indicate more symptoms. 
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Figure A4.4 Marginal effects of clinical features on number of inpatient admissions 
Figure A4.4 Legend. Dashed lines represent 95% confidence interval. Marginal effects represent the change in number of 
inpatient admission associated with a change (1 point decline in cognition, or 1 point increase in function and 
behavioral/psychological symptoms) from better to poorer for each clinical feature. Higher cognitive scores indicate 
greater cognitive abilities. Higher functional scores indicate more functional limitations. Higher behavioral/psychological 
scores indicate more symptoms. 
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Figure A4.5 Marginal effects of clinical features on number of Medicare covered skilled nursing days 
Figure A4.5 Legend. Dashed lines represent 95% confidence interval. Marginal effects represent the change in number 
of Medicare covered skilled nursing days associated with a change (1 point decline in cognition, or 1 point increase in 
function and behavioral/psychological symptoms) from better to poorer for each clinical feature. Higher cognitive scores 
indicate greater cognitive abilities. Higher functional scores indicate more functional limitations. Higher 
behavioral/psychological scores indicate more symptoms. 		
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Figure A4.6 Marginal effects of clinical features on number of institutional outpatient visits    
Figure A4.6 Legend. Dashed lines represent 95% confidence interval. Marginal effects represent the change in 
institutional outpatient visits associated with a change (1 point decline in cognition, or 1 point increase in function and 
behavioral/psychological symptoms) from better to poorer for each clinical feature. Higher cognitive scores indicate 
greater cognitive abilities. Higher functional scores indicate more functional limitations. Higher behavioral/psychological 
scores indicate more symptoms. 	
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Figure A4.7 Marginal effects of clinical features on number of physician visits 
Figure A4.7 Legend. Dashed lines represent 95% confidence interval. Marginal effects represent the change in number 
of physician visits (evaluation and management) associated with a change (1 point decline in cognition, or 1 point 
increase in measure of function and behavioral/psychological symptoms) from better to poorer for each clinical feature. 
Higher cognitive scores indicate greater cognitive abilities. Higher functional scores indicate more functional limitations. 
Higher behavioral/psychological scores indicate more symptoms.
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Table A5.1 Data source of variables used in regression models 
Variable Data Source 
Outcome Measures  
Out-of-pocket medical and nursing home 
expenditures 
HRS 
Time spent caregiving  ADAMS 
Main Effects  
Mini-Mental State Examination ADAMS 
Number of functional limitations  ADAMS 
Number of behavioral and psychological 
symptoms 
ADAMS 
Control Variables  
Age ADAMS 
Gender ADAMS 
Race ADAMS 
Marital status ADAMS 
Medicaid HRS 
Long-term care insurance HRS 
Supplemental insurance HRS 
Household income HRS 
Number of children HRS 
HRS-proxy respondent HRS 
Time between ADAMS and HRS assessment ADAMS/HRS 
Caregiver relationship ADAMS 
Caregiver live with person with dementia ADAMS 
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Table A5.2 Baseline sample characteristics of individuals included/excluded from expenditure analysis 
 Linking ADAMS to nearest available HRS Wave Linking ADAMS to following HRS Wave 
Variable All ADAMS 
respondents 
identified as 
having 
dementia (n = 
308) 
Respondents 
with dementia 
excluded from 
out-of-pocket 
spending 
analysis due 
to missing 
data (n = 93) 
Respondents 
included in 
out-of-pocket 
spending 
analysis (n = 
215) 
All ADAMS 
respondents 
identified as 
having 
dementia (n 
= 308) 
Respondents 
with dementia 
excluded from 
out-of-pocket 
spending 
analysis due 
to missing 
data (n = 123) 
Respondents 
included in 
out-of-pocket 
spending 
analysis (n = 
185) 
Mean cognition (SD), 
MMSE 
16.01 (11.11) 15.82 (12.68) 16.05 (10.54) 16.01 
(11.11) 
15.58 (12.77) 16.18 (10.42) 
Mean number 
functional limitations 
(SD)  
6.32 (3.53) 7.08 (3.27) 6.02 (3.49)* 6.32 (3.53) 6.81 (3.66) 6.04 (3.36) 
Mean number of 
behaviors/psychological 
symptoms (SD) 
2.56 (3.72) 2.24 (3.43) 2.68 (3.78) 2.56 (3.72) 2.29 (3.61) 2.71 (3.72) 
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Mean age (SD), y 84.18 (10.36) 86.09 (10.20) 83.42 (10.16)* 84.18 
(10.36) 
85.91 (10.21) 83.19 
(10.07)* 
Male,  % 31.10 21.00 35.13 31.10 26.70 33.63 
Non-Caucasian, % 20.11 21.50 19.57 20.11 20.37 19.97 
Married, % 23.02 19.02 24.60 23.02 23.32 22.85 
Long-term care 
insurance, % 
3.32 4.99 2.72 5.30 9.11 4.60 
Medicaid, %  30.50 40.90 27.31† 33.19 33.74 33.11 
Supplemental 
Insurance (e.g., 
Medigap),% 
26.68 31.84 24.86 20.72 9.85 22.48 
Mean household 
income (SD), $, in 
thousands  
20.58 (31.07) 18.73 (27.20) 21.30 (32.24) 20.86 
(33.91) 
18.52 (29.87) 21.37 (33.47) 
Mean number of 
children (SD)  
2.76 (4.30) 2.44 (3.62) 2.87 (4.47) 2.91 (4.59) 2.54 (3.24) 2.98 (4.60) 
Mean number of 
comorbidities (SD) 
2.92 (2.33) 2.93 (2.45) 2.92 (2.28)† 2.32 (2.87) 1.17 (2.95) 2.99 (2.21)* 
Proxy respondent, % 46.88 44.84 47.69 35.02 15.62 46.13* 
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Mean months between 
ADAMS and HRS 
assessments (SD) 
8.18 (6.36) 10.10 (8.88) 7.42 (4.63)*† 10.64 (8.99) 10.39 (9.12) 10.69 (8.69) 
Mean monthly out-of-
pocket medical 
expenditures (SD), $ 
231.21 
(596.72) 
329.76 
(921.37) 
192.39 
(405.84) 
273.00 
(880.76) 
540.88 
(1522.37) 
214.76 
(625.46)* 
Mean monthly out-of-
pocket nursing home 
expenditures (SD), $ 
632.36 
(2991.61) 
649.77 
(3130.09) 
625.50 
(2936.60) 
681.85 
(3042.08) 
752.88 
(2772.56) 
666.50 
(2990.44) 
Notes: Two comparisons were made.  First, we compared those included/excluded within the same linking method. 
Second, we compared those included across linking methods. Continuous variables were compared using two-sided 
Students t-test and categorical variables were compared using chi-square test.  
*Indicates there is a statistically significant difference (p < 0.05) between those included/excluded from the analysis.   
†Indicates there is a statistically significant difference (p < 0.05) between those included in the analysis based on sample 
selection method.     
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Table A5.3 Baseline sample characteristics of individuals included/excluded from time caregiving analysis 
 Linking ADAMS to nearest available HRS Wave Linking ADAMS to following HRS Wave 
Variable All ADAMS 
respondents 
identified as 
having 
dementia (n = 
308) 
Respondents 
with dementia 
excluded from 
time spent 
caregiving 
analysis due 
to missing 
data (n =177) 
Respondents 
included in the 
time spent 
caregiving 
analysis  (n = 
131) 
All ADAMS 
respondents 
identified as 
having 
dementia (n 
= 308) 
Respondents 
with dementia 
excluded from 
time spent 
caregiving 
analysis due 
to missing 
data (n = 196) 
Respondents 
included in 
the time 
spent 
caregiving 
analysis  (n = 
112) 
Mean cognition (SD), 
MMSE 
16.01 (11.11) 14.47 (11.13) 17.89 (9.96)* 16.01 
(11.11) 
14.63 (11.36) 18.17 (9.35)* 
Mean number of 
functional limitations 
(SD)  
6.32 (3.53) 6.88 (3.17) 5.48 (3.61)* 6.32 (3.53) 6.79 (3.31) 5.43 (3.47)* 
Mean number of 
behaviors/psychological 
symptoms (SD) 
2.56 (3.72) 2.68 (3.58) 2.40 (3.88) 2.56 (3.72) 2.68 (3.70) 2.36 (3.71) 
Mean age (SD), y 84.18 (10.36) 84.72 (10.42) 83.36 (10.08)* 84.18 84.77 (10.46) 83.06 (9.88)* 
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(10.36) 
Male,  % 31.10 26.36 38.22 31.10 28.73 35.58 
Non-Caucasian, % 20.11 21.80 17.57 20.11 21.09 18.26 
Married, % 23.02 18.48 29.84 23.02 21.58 25.74 
Long-term care 
insurance, % 
3.32 2.88 3.94 5.30 1.57 9.67* 
Medicaid, %  30.50 36.00 23.00 33.19 38.15 27.61 
Supplemental 
Insurance (e.g., 
Medigap),% 
26.68 26.80 26.51 20.72 17.18 
 
24.86 
Mean household 
income (SD), $, in 
thousands  
20.58 (31.07) 18.52 (28.40) 23.67 (34.34)* 20.86 
(33.91) 
17.97 (26.16) 24.42 
(40.42)* 
Mean number of 
children (SD)  
2.76 (4.30) 2.53 (4.60) 3.07 (3.70) 2.91 (4.59) 2.80 (5.08) 3.03 (3.63) 
Mean number of 
comorbidities (SD) 
2.92 (2.33) 3.10 (2.40) 2.66 (2.13) 2.32 (2.87) 2.09 (3.08) 2.78 (2.18)* 
Proxy respondent, % 46.88 54.61 35.27 35.02 34.71 35.60 
Mean months between 8.18 (6.36) 8.58 (6.60) 7.57 (5.76)† 10.64 (8.99) 10.01 (8.08) 11.43 (9.63) 
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ADAMS and HRS 
assessments (SD) 
Mean time providing 
any caregiving (SD) 
125.63 
(305.86) 
112.06 
(274.66) 
138.99 
(322.31) 
125.63 
(305.86) 
122.93 
(294.20) 
129.12 
(307.37) 
Caregiver 
Characteristics 
      
Relationship        
Spouse, % 19.67 13.87 26.88* 19.67 16.12 25.30* 
Child, % 48.90 42.81 56.45 48.90 42.39 59.22 
Other, % 31.42 43.32 16.67 31.42 41.48 15.48 
Live with person with 
dementia, % 
42.64 26.42 60.36* 42.64 30.80 58.70* 
Notes: Two comparisons were made.  First, we compared those included/excluded within the same linking method. 
Second, we compared those included across linking methods. Continuous variables were compared using two-sided 
Students t-test and categorical variables were compared using chi-square test.  
*Indicates there is a statistically significant difference (p < 0.05) between those included/excluded from the analysis.   
†Indicates there is a statistically significant difference (p < 0.05) between those included in the analysis based on sample 
selection method.
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Table A5.4 Comparison between Functional Activities Questionnaire and investigator modified version of Functional 
Activities Questionnaire 
Functional Activities Questionnaire Investigator modified version of Functional Activities Questionnaire 
based on survey items in Aging, Demographics, and Memory Study  
Question Stem: “In the past 
four weeks, did the subject 
have any difficulty or need help 
with” 
Response Question Stem: Response (Coded: 0 = 
no limitation; 1 = 
limitation  
1. Writing checks, paying bills, 
or balancing a checkbook. 
Normal; Has 
difficulty, but 
does by self; 
Requires 
assistance; 
Dependent 
1. Rate her/his ability to handle small 
sums of money (e.g. making change, 
leaving a small tip, shopping) 
No loss (0); Some loss 
(1); Severe loss (1) 
2. Assembling tax records, 
business affairs, or other 
papers. 
2. Rate her/his ability to handle 
complicated financial or business 
transactions (e.g., balancing a 
checkbook, paying bills, doing 
banking, handling investment) 
No loss (0); Some loss 
(1); Severe loss (1) 
3. Shopping alone for clothes, 
household necessities, or 
3. Is (s/he) able to independently shop 
for her/his needs? 
Usually (0); Sometimes 
(1); Rarely (1) 
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groceries. 
4. Playing a game of skill 
such as bridge or chess, 
working on a hobby. 
4. Does (s/he) have more difficulty than 
in the past performing her/his 
hobbies?  Hobbies may include things 
like sewing, painting, handicrafts, 
reading, entertaining, photography, 
gardening, going to theater or 
symphony, woodworking, participating 
in sports. 
No (0); Little (1); Some 
(1); Much (1) 
5. Heating water, making a 
cup of coffee, turning off 
the stove. 
5. First, does (s/he) have more difficulty 
than in the past carrying out routine 
household tasks, such as cooking, 
cleaning, laundry, taking out garbage, 
yard work, simple maintenance and 
home repair? 
No (0); Little (1); Some 
(1); Much (1)  
6. Preparing a balanced meal. 6. Does (s/he) have difficulty with feeding 
her/himself? 
No (0); Yes (1) 
7. Keeping track of current 
events. 
7. Rate subject's LOSS of ability to: 
Recall recent events 
None (0); Some (1); 
Severe (1) 
8. Paying attention to and 8. Does (s/he) seem less able to No (0); Little less (1); 
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understanding a TV 
program, book, or 
magazine. 
understand what (s/he) reads? 
Or Does (s/he) seem less able to 
understand what (s/he) sees on TV? 
Much less (1) 
9. Remembering 
appointments, family 
occasions, holidays, 
medications.  
9. Compared with two years ago, how is 
your friend or relative at remembering 
things about family and friends, such 
as occupations, birthdays and 
addresses? 
Much better (0); A bit 
better (0); Not much 
change (0); A bit worse 
(1); Much worse (1) 
10. Traveling out of the 
neighborhood, driving, or 
arranging to take public 
transportation.  
 
10. Let(s talk about her/his ability to find 
her/his way around places. Does 
(s/he) have more difficulty than in the 
past with finding his/her way around 
familiar streets outside the 
neighborhood? 
No (0); Yes (1) 
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Table A5.5 Regression coefficients from two-part model for average monthly out-of-pocket health care expenditures 
(excluding nursing home expenditures)  
 Logistic Regression – Any out of 
pocket expenditures (n = 215) 
Generalized Linear Model (log link 
gamma distribution) – Positive 
expenditures (n = 155) 
 Unadjusted Adjusted Unadjusted Adjusted 
Intercept  -0.19 -6.35 4.05 6.75    
 (-2.09 , 1.70) (-14.46 , 1.77) (3.19 , 4.91) (3.71 , 9.80) 
Cognition 0.13 0.06 0.05 0.04   
 (0.04 , 0.22) (-0.02 , 0.14) (0.02 , 0.08) (0.01 , 0.06) 
Function 0.02 -0.04 0.09 0.10  
 (-0.19 , 0.23) (-0.39 , 0.31) (0.01 , 0.16) (0.01 , 0.18) 
Behavioral/psychological symptoms -0.18 -0.22 0.03 0.02 
 (-0.38 , 0.03) (-0.47 , 0.03) (-0.07 , 0.12) (-0.06 , 0.09) 
Age  0.09  -0.03 
  (-0.01 , 0.19)  (-0.06 , 0.01) 
Male  0.22  -0.15 
  (-0.70 , 1.14)  (-0.50 , 0.20) 
Non-Caucasian (ref = white)  1.23  -0.30 
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  (0.01 , 2.45)  (-0.75 , 0.16) 
Married (ref = not married)  0.26  -0.45 
  (-0.45 , 0.98)  (-0.91 , 0.01) 
Medicaid (ref = no)  -2.11  -0.09 
  (-3.21 , -1.01)  (-0.48 , 0.30) 
Supplemental insurance (ref = no)  1.17  0.13 
  (-0.26 , 2.60)  (-0.29 , 0.55) 
Household income (per $1,000)  0.02  0.01 
  (-0.03 , 0.06)  (0.00 , 0.02) 
Number of children   -0.17  0.03 
  (-0.36 , 0.03)  (-0.07 , 0.14) 
Number of comorbidities  0.37  0.02 
  (0.09 , 0.64)  (-0.08 , 0.12) 
Proxy Respondent (ref = no)  -0.76  -0.21 
  (-1.89 , 0.37)  (-0.62 , 0.21) 
Time between ADAMS and following 
HRS assessment 
 
0.00  0.00 
  (-0.01 , 0.00)  (-0.00 , 0.00) 
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Table A5.6 Regression coefficients from two-part model for average monthly out-of-pocket nursing home expenditures  
 Logistic Regression – Any out of 
pocket nursing home expenditures (n 
= 215) 
Generalized Linear Model (log link 
gamma distribution) – Positive 
expenditures (n = 43) 
 Unadjusted Adjusted Unadjusted Adjusted 
Intercept  -2.54 0.23 6.20 9.45 
 (-5.48 , 0.40) (-6.75 , 7.22) (2.13 , 10.26) (3.90 , 15.01) 
Cognition -0.07 -0.08 -0.01 -0.03 
 (-0.15 , 0.02) (-0.21 , 0.05) (-0.10 , 0.09) (-0.11 , 0.05) 
Function 0.40 0.36 0.29 -0.13 
 (0.08 , 0.72) (0.05 , 0.67) (-0.29 , 0.88) (-0.88 , 0.61) 
Behavioral/psychological symptoms -0.05 -0.11 -0.15 0.00 
 (-0.24 , 0.13) (-0.31 , 0.09) (-0.56 , 0.25) (-0.38 , 0.38) 
Age  -0.03   
  (-0.10 , 0.04)   
Male  0.54   
  (-0.55 , 1.62)   
Non-Caucasian (ref = white)  -1.67   
  (-2.89 , -0.45)   
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Married (ref = not married)  -1.74   
  (-3.12 , -0.36)   
Medicaid (ref = no)  -0.87  -1.91 
  (-2.14 , 0.39)  (-3.36 , -0.45) 
Long-term care insurance (ref = no)  -0.37  -3.45 
  (-2.67 , 1.92)  (-5.33 , -1.58) 
Supplemental insurance (ref = no)  -0.71   
  (-1.61 , 0.19)   
Household income (per $1,000)  0.02   
  (0.00 , 0.03)   
Number of children   0.04   
  (-0.14 , 0.21)   
Number of comorbidities  0.17   
  (-0.20 , 0.54)   
Proxy Respondent (ref = no)  0.82   
  (-0.74 , 2.39)   
Time between ADAMS and following 
HRS assessment 
 
0.00 
 
 
  (-0.01 , 0.00)   
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Table A5.7 Regression coefficients from two-part model for average monthly time spent providing active help 
 Logistic regression – any time 
providing active help (n = 129) 
Generalized Linear Model (log link 
gamma distribution) – positive time 
providing active help (n = 86) 
 Unadjusted Adjusted Unadjusted Adjusted 
Intercept  -1.51 -8.46 4.74 1.54 
 (-5.37 , 2.35) (-17.89 , 0.97) (2.95 , 6.52) (-0.79 , 3.87) 
Cognition -0.05 -0.02 -0.03 -0.03 
 (-0.21 , 0.11) (-0.20 , 0.16) (-0.08 , 0.03) (-0.08 , 0.01) 
Function 0.30 0.45 0.17 0.19 
 (-0.04 , 0.65) (0.03 , 0.87) (-0.01 , 0.35) (0.06 , 0.32) 
Behavioral/psychological symptoms 0.33 0.37 -0.04 -0.02 
 (0.08 , 0.58) (0.15 , 0.60) (-0.11 , 0.02) (-0.10 , 0.07) 
Age  0.03  0.03 
  (-0.06 , 0.11)  (-0.01 , 0.06) 
Male  -0.66   
  (-1.89 , 0.56)   
Non-Caucasian (ref = white)  0.32   
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  (-1.30 , 1.94)   
Medicaid (ref = no)  -0.93  0.37 
  (-2.59 , 0.72)  (-0.11 , 0.86) 
Household income (per $1,000)  0.00   
  (-0.02 , 0.02)   
Number of children  -0.01   
  (-0.23 , 0.21)   
Number of comorbidities  0.44  0.02 
  (-0.01 , 0.89)  (-0.11 , 0.14) 
Caregiver relationship (ref = spouse)     
Child  1.81  -0.08 
  (-0.25 , 3.86)  (-0.85 , 0.68) 
Other  2.78  0.02 
  (0.29 , 5.27)  (-0.78 , 0.83) 
Caregiver live with person with 
dementia (ref = does not live with 
person) 
 
1.78  1.04 
  (-0.18 , 3.74)  (0.52 , 1.56) 
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Table A5.8 Regression coefficients from two-part model for average monthly time spent providing supervision 
 Logistic regression – any time 
providing supervision (n = 124) 
Generalized Linear Model (log link 
gamma distribution) – positive time 
providing supervision (n = 80) 
 Unadjusted Adjusted Unadjusted Adjusted 
Intercept  -0.59 -5.79 3.97 1.55 
 (-4.11 , 2.93) (-17.36 , 5.78) (2.14 , 5.79) (-1.10 , 4.21) 
Cognition -0.10 -0.07 0.00 -0.01 
 (-0.25 , 0.04) (-0.25 , 0.12) (-0.05 , 0.05) (-0.06 , 0.04) 
Function 0.30 0.52 0.24 0.27 
 (-0.06 , 0.66) (0.12 , 0.91) (0.06 , 0.41) (0.19 , 0.36) 
Behavioral/psychological symptoms 0.28 0.34 -0.04 -0.01 
 (0.01 , 0.55) (0.01 , 0.66) (-0.12 , 0.04) (-0.10 , 0.08) 
Age  0.01  0.02 
  (-0.10 , 0.12)  (-0.01 , 0.05) 
Male  0.02   
  (-1.50 , 1.54)   
Non-Caucasian (ref = white)  1.13   
  (-0.39 , 2.64)   
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Medicaid (ref = no)  -0.33  0.41 
  (-1.94 , 1.28)  (-0.01 , 0.82) 
Household income (per $1,000)  -0.01   
  (-0.05 , 0.02)   
Number of children  -0.24   
  (-0.56 , 0.08)   
Number of comorbidities  0.60  0.01 
  (0.04 , 1.16)  (-0.09 , 0.11) 
Caregiver relationship (ref = spouse)     
Child  1.00  -0.43 
  (-0.95 , 2.94)  (-0.94 , 0.08) 
Other  1.21  -0.24 
  (-0.90 , 3.31)  (-0.71 , 0.24) 
Caregiver live with person with 
dementia (ref = does not live with 
person) 
 
1.44  1.07 
  (-0.07 , 2.95)  (0.57 , 1.56) 
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Table A5.9 Regression coefficients from two-part model for average monthly time spent providing any caregiving 
 Logistic regression – any time 
providing any caregiving (n = 131) 
Generalized Linear Model (log link 
gamma distribution) – positive time 
providing any caregiving (n = 91) 
 Unadjusted Adjusted Unadjusted Adjusted 
Intercept  -0.70 -5.44 5.31 2.53 
 (-4.46 , 3.06) (-16.14 , 5.25) (3.86 , 6.75) (0.28 , 4.79) 
Cognition -0.08 -0.05 -0.03 -0.03 
 (-0.24 , 0.09) (-0.23 , 0.14) (-0.08 , 0.02) (-0.08 , 0.01) 
Function 0.29 0.44 0.12 0.15 
 (-0.05 , 0.63) (0.03 , 0.84) (-0.01 , 0.25) (0.06 , 0.24) 
Behavioral/psychological symptoms 0.28 0.30 -0.01 0.01 
 (0.02 , 0.54) (0.03 , 0.57) (-0.07 , 0.05) (-0.08 , 0.09) 
Age  0.01  0.02 
  (-0.09 , 0.11)  (-0.00 , 0.05) 
Male  -0.42   
  (-1.86 , 1.02)   
Non-Caucasian (ref = white)  0.98   
  (-0.50 , 2.46)   
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Medicaid (ref = no)  -0.71  0.43 
  (-2.32 , 0.90)  (0.07 , 0.79) 
Household income (per $1,000)  0.00   
  (-0.04 , 0.03)   
Number of children  -0.09   
  (-0.44 , 0.25)   
Number of comorbidities  0.49  0.04 
  (-0.03 , 1.00)  (-0.05 , 0.13) 
Caregiver relationship (ref = spouse)     
Child  1.12  -0.05 
  (-0.81 , 3.05)  (-0.62 , 0.53) 
Other  1.75  -0.07 
  (-0.07 , 3.58)  (-0.79 , 0.65) 
Caregiver live with person with 
dementia (ref = does not live with 
person) 
 
1.57  0.83 
  (-0.16 , 3.29)  (0.38 , 1.28) 
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Table A6.1 Baseline demographic characteristics 
 Estimate Source1 
Characteristics of person with dementia   
Mean age of dementia onset (SD), y 83.67 (5.26) ADAMS 
Male, % 33.00 ADAMS  
Mean education2 (SD), y 10.87 (4.16) ADAMS 
Race, %   
White 85.00 NACC-UDS 
African American 9.00 NACC-UDS 
Other 6.00 NACC-UDS 
Marital Status, %   
Married 34.00 ADAMS 
Widowed  55.00 ADAMS 
Other 11.00 ADAMS 
Region of residence, %   
Northeast 30.00 NACC-UDS 
South 10.00 NACC-UDS 
West 46.00 NACC-UDS 
Midwest 14.00 NACC-UDS 
Long-term care insurance, % 19.00 ADAMS 
Medicaid3, % 15.00 ADAMS 
Mean household income4 (SD), $ 30,827 (28,008) ADAMS 
Mean number of children5 (SD) 3.12 (1.81) ADAMS 
Comorbidities, %    
Hypertension 68.00 NACC-UDS 
Diabetes 16.00 NACC-UDS 
Congestive heart failure 7.00 NACC-UDS 
Stroke 11.00 NACC-UDS 
Hypercholesterolemia 66.00 NACC-UDS 
Psychiatric problems 11.00 NACC-UDS 
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Characteristics of caregiver   
Caregiver relationship to person with 
dementia6, % 
  
Child 53.00 ADAMS 
Other family  19.00 ADAMS 
Other 28.00 ADAMS 
Caregiver lives with person with dementia7, % 39.00 ADAMS 
Model specific parameters8    
Proxy-respondent, % 9.00 ADMAS 
Mean number of days between ADAMS and 
HRS assessment (SD) 
186.33 (130.37) ADAMS 
Abbreviations: ADAMS = Aging, Demographics, and Memory Study; NACC = 
National Alzheimer’s Coordinating Center Uniform Data Set; HRS = Health and 
Retirement Study. 
1ADAMS survey weights were used. 
2Number of years of education was bound between 5 and 18 years. 
3Medicaid status at time of diagnosis. The probability of transitioning to Medicaid 
was modeled as a separate risk (Table 1).  
4For individuals on Medicaid mean household income was $9,452 (SD = 4,500) 
5We assumed the maximum number of kids per family was 5. The model 
rounded the predicted number of kids to the nearest integer.  
6In the model, if a person with dementia was predicted to be married we 
assumed the spouse was the primary caregiver. The percentages represent the 
conditional proportions assuming the person with dementia is not married.   
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7In the model, if a person with dementia was predicted to be married we 
assumed they lived with someone. The percentage represent the conditional 
proportion assuming the person with dementia is not married. 
8The regression equations predicting out-of-pocket expenditures controlled for if 
a proxy-respondent provided answers to survey questions and the time between 
the core HRS survey and ADAMS survey. 
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Table A6.2 Functional domains  
Functional Domains  
1. Writing checks, paying bills, or balancing a checkbook 
2. Assembling tax records, business affairs, or other papers 
3. Shopping alone for clothes, household necessities, or groceries 
4. Playing a game of skill such as bridge or chess, working on a 
hobby 
5. Heating water, making a cup of coffee, turning off the stove 
6. Preparing a balanced meal 
7. Keeping track of current events 
8. Paying attention to and understanding a TV program, book, or 
magazine 
9. Remembering appointments, family occasions, holidays, or 
medications 
10. Traveling out of the neighborhood, driving or arranging to take 
public transportation 
Notes: Measure of function is scored from 0-10 with high scores indicating more 
limitations.  If a limitation is present for a given domain than an individual 
receives a score of 1 otherwise they receive a score of 0.
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Table A6.3 Behavioral/psychological symptom domains  
Behavioral Psychological Symptoms of Dementia Domains 
1. Delusions 
2. Hallucinations 
3. Agitation or aggression 
4. Depression or dysphoria 
5. Anxiety 
6. Elation or euphoria 
7. Apathy or indifference 
8. Disinhibition 
9. Irritability or lability 
10. Motor disturbance 
11. Nighttime behaviors 
12. Changes in appetite and eating 
Notes: Domains are based on Neuropsychiatric Inventory Questionnaire version 
Q. The measure of behavioral/psychological symptoms is scored from 0-12 with 
high scores indicating more symptoms. If a behavior is present for a given 
domain than an individual receives a score of 1 otherwise they receive a score of 
0. 
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Table A6.4 Linear mixed effects regression model coefficients for cognitive 
trajectories 
Variable  Coefficient  
(95% Confidence Interval) 
Intercept 20.328 
 (15.849 , 24.807) 
Time -0.321 
 (-0.504 , -0.137) 
Time2 -0.001 
 (-0.001 , -0.001) 
Age of Onset (Years) 0.001 
 (-0.046 , 0.048) 
Age of Onset (Years) * Time 0.003 
 (0.001 , 0.005) 
Male  0.231 
 (-0.366 , 0.827) 
Years of Education 0.236 
 (0.141 , 0.331) 
Race (ref = White)  
African American -1.629 
 (-2.640 , -0.618) 
Other -0.274 
 (-1.558 , 1.010) 
Marital Status (ref = Widowed)  
Married -0.582 
 (-1.241 , 0.077) 
Other -0.039 
 (-1.070 , 0.991) 
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Region of Residence (ref = Northeast)  
South 0.025 
 (-1.245 , 1.294) 
West -1.192 
 (-2.015 , -0.368) 
Midwest 1.197 
 (0.166 , 2.228) 
Not Specified  -0.192 
 (-0.971 , 0.587) 
Region of Residence (ref = Northeast) 
* Time  
South  -0.029 
 (-0.092 , 0.034) 
West -0.061 
 (-0.103 , -0.021) 
Midwest 0.007 
 (-0.043 , 0.057) 
Not Specified  -0.023 
 (-0.061 , 0.015) 
Community-dwelling in Previous Time 
Period (ref = Facility) 0.474 
 (-0.393 , 1.341) 
Hypertension at Diagnosis 0.418 
 (-0.193 , 1.029) 
Hypertension at Diagnosis * Time 0.031 
 (0.002 , 0.060) 
Diabetes at Diagnosis -0.216 
 (-1.030 , 0.597) 
Congestive Heart Failure at Diagnosis 0.207 
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 (-0.923 , 1.337) 
Congestive Heart Failure at Diagnosis 
* Time 0.058 
 (0.003 , 0.114) 
Stroke at Diagnosis -0.315 
 (-1.145 , 0.515) 
Hypercholesterolemia at Diagnosis 0.249 
 (-0.362 , 0.861) 
Psychiatric Problems at Diagnosis 0.794 
 (-0.086 , 1.674) 
Notes: Model is estimated using data from the National Alzheimer’s Coordinating 
Center Uniform Data Set. Cognition is evaluated using the Mini-mental State 
Exam (scored 0 – 30). Coefficients were used to predict monthly change in 
cognition. Higher scores indicate greater cognitive abilities. Model is based on 
Jutkowitz, E, et al. "Risk Factors Associated with Cognitive, Functional, and 
Behavioral Trajectories of Newly Diagnosed Dementia Patients." The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences (2016). 
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Table A6.5 Linear mixed effects regression model coefficients functional 
trajectories  
Variable Coefficient  
(95% Confidence Interval) 
Intercept 12.031 
 (8.588 , 15.475) 
Time 0.056 
 (0.008 , 0.104) 
Time2 -0.001 
 (-0.001 , -0.001) 
Cognitive Status -0.176 
 (-0.223 , -0.129) 
Cognitive Status * Time 0.000 
 (-0.001 , 0.001) 
Age of Onset (Years) -0.010 
 (-0.043 , 0.023) 
Male  -0.791 
 (-1.220 , -0.362) 
Years of Education -0.051 
 (-0.133 , 0.031) 
Years of Education * Time 0.002 
 (0.000 , 0.004) 
Race (ref = White)  
African American -1.067 
 (-1.768 , -0.365) 
Other -0.062 
 (-0.948 , 0.823) 
Marital Status (ref = Widowed)  
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Married -0.642 
 (-1.189 , -0.095) 
Other -0.150 
 (-0.870 , 0.569) 
Region of Residence (ref = Northeast)  
South -0.194 
 (-1.070 , 0.682) 
West 0.537 
 (-0.032 , 1.107) 
Midwest -0.937 
 (-1.640 , -0.234) 
Not Specified  -0.182 
 (-0.712 , 0.348) 
Community-dwelling in Previous Time 
Period (ref = Facility) -1.287 
 (-2.261 , -0.314) 
Community-dwelling in Previous Time 
Period (ref = Facility) * Time 0.027 
 (0.002 , 0.051) 
Informant Relationship (ref = Spouse)  
Other Family Member -0.479 
 (-0.983 , 0.025) 
Other -0.637 
 (-1.336 , 0.063) 
Hypertension at Diagnosis -0.029 
 (-0.452 , 0.393) 
Diabetes at Diagnosis 0.261 
 (-0.432 , 0.955) 
Diabetes at Diagnosis * Time -0.014 
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 (-0.031 , 0.003) 
Congestive Heart Failure at Diagnosis  0.060 
 (-0.719 , 0.838) 
Stroke at Diagnosis 0.895 
 (0.333 , 1.456) 
Hypercholesterolemia at Diagnosis -0.456 
 (-0.884 , -0.029) 
Psychiatric Problems at Diagnosis -0.210 
 (-0.820 , 0.401) 
Notes: Data for the model is from the National Alzheimer’s Coordinating Center 
Uniform Data Set. Function is evaluated as the number of functional limitations 
(scored 0 – 10). Coefficients were used to predict monthly change in function. 
Higher scores indicate more functional limitations.  Model is based on Jutkowitz, 
E, et al. "Risk Factors Associated with Cognitive, Functional, and Behavioral 
Trajectories of Newly Diagnosed Dementia Patients." The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences (2016). 
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Table A6.6 Linear mixed effects regression model coefficients behavioral and 
psychological symptoms trajectories 
Variable Coefficient  
(95% Confidence Interval) 
Intercept 6.722 
 (3.910 , 9.534) 
Time 0.048 
 (0.017 , 0.079) 
Time2 0.000 
 (0.000 , 0.000) 
Cognitive Status -0.044 
 (-0.084 , -0.004) 
Cognitive Status * Time -0.001 
 (-0.002 , 0.000) 
Age of Onset (Years) -0.048 
 (-0.076 , -0.019) 
Male  0.101 
 (-0.307 , 0.510) 
Male * Time -0.014 
 (-0.027 , -0.001) 
Years of Education -0.015 
 (-0.072 , 0.042) 
Race (ref = White)  
African American -0.336 
 (-0.936 , 0.264) 
Other -0.045 
 (-0.808 , 0.718) 
Marital Status (ref = Widowed)  
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Married 0.123 
 (-0.365 , 0.612) 
Other 0.661 
 (0.031 , 1.291) 
Region of Residence (ref = Northeast)  
South 1.128 
 (0.378 , 1.879) 
West 0.342 
 (-0.148 , 0.832) 
Midwest 0.282 
 (-0.328 , 0.892) 
Not Specified  0.654 
 (0.194 , 1.114) 
Community-dwelling in Previous Time 
Period (ref = Facility) 0.382 
 (-0.120 , 0.885) 
Informant Relationship (ref = Spouse)  
Other Family Member -0.053 
 (-0.552 , 0.445) 
Other -0.273 
 (-1.019 , 0.474) 
Informant Relationship (ref = Spouse) * 
Time  
Other Family Member -0.009 
 (-0.023 , 0.004) 
Other -0.015 
 (-0.034 , 0.004) 
Hypertension at Diagnosis 0.332 
 (-0.031 , 0.695) 
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Diabetes at Diagnosis 0.402 
 (-0.081 , 0.885) 
Congestive Heart Failure at Diagnosis 0.380 
 (-0.288 , 1.047) 
Stroke at Diagnosis 0.475 
 (-0.199 , 1.149) 
Stroke at Diagnosis * Time -0.017 
 (-0.038 , 0.004) 
Hypercholesterolemia at Diagnosis -0.406 
 (-0.769 , -0.043) 
Psychiatric Problems at Diagnosis 0.832 
 (0.307 , 1.356) 
Notes: Data for the model is from the National Alzheimer’s Coordinating Center 
Uniform Data Set. Behavior and psychological symptoms is evaluated as number 
of symptoms (scored 0 – 12). Coefficients were used to predict monthly change 
in behavioral and psychological symptoms. Higher scores indicate more 
symptoms.  Model is based on Jutkowitz, E, et al. "Risk Factors Associated with 
Cognitive, Functional, and Behavioral Trajectories of Newly Diagnosed Dementia 
Patients." The Journals of Gerontology Series A: Biological Sciences and 
Medical Sciences (2016). 
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Table A6.7 Weibull model regression coefficients for time to long-term care 
facility placement 
Variable Coefficient  
(95% Confidence Interval) 
Intercept -10.32 
 (-11.62 , -9.02) 
Cognitive Status in Previous Time 
Period  -0.03 
 (-0.04 , -0.02) 
Functional Limitations in Previous Time 
Period 0.08 
 (0.05 , 0.11) 
Behavioral and Psychological 
Symptoms in Previous Time Period 0.09 
 (0.06 , 0.12) 
Live With Someone Alone (ref = Lives 
Alone)  -1.06 
 (-1.24 , -0.87) 
Age of Onset (Years) 0.02 
 (0.01 , 0.04) 
Male  -0.19 
 (-0.36 , -0.03) 
Years of Education 0.05 
 (0.03 , 0.07) 
Race (ref = White)  
African American -0.59 
 (-0.88 , -0.30) 
Other -0.52 
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 (-0.90 , -0.14) 
Region of Residence (ref = Northeast)  
South 0.12 
 (-0.32 , 0.56) 
West 0.78 
 (0.56 - 1.00) 
Midwest 0.60 
 (0.27 , 0.93) 
Not Specified  0.45 
 (0.23 , 0.67) 
Hypertension at Diagnosis -0.06 
 (-0.22 , 0.10) 
Diabetes at Diagnosis 0.00 
 (-0.22 , 0.22) 
Congestive Heart Failure at Diagnosis 0.16 
 (-0.15 , 0.48) 
Stroke at Diagnosis -0.13 
 (-0.39 , 0.13) 
Hypercholesterolemia at Diagnosis -0.11 
 (-0.28 , 0.05) 
Psychiatric Problems at Diagnosis 0.24 
 (0.01 , 0.47) 
Weibull shape parameter 1.80 
 (1.72 , 1.88) 
Notes: Data for the model is from the National Alzheimer’s Coordinating Center 
Uniform Data Set. Coefficients were used to predict monthly risk of entering a 
long-term care facility.  
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Table A6.8 Two-part model regression coefficients for time spent receiving 
formal caregiving 
Variable Logistic 
Regression – 
Probability of 
Receiving Formal 
Caregiving 
Generalized Linear 
Model (log link 
gamma distribution) 
– Amount of Formal 
Caregiving Received  
Intercept  -14.05 3.74 
 (-29.21 , 1.12) (-1.20 , 0.07) 
Cognition 0.065 -0.01 
 (-0.02 , 0.15) (-0.08 , 0.07) 
Function 0.29 0.20 
 (-0.09 , 0.68) (0.47 , 0.87) 
Behavioral and Psychological 
Symptoms -0.05 0.15 
 (-0.21 , 0.11) (-0.01 , 0.30) 
Age 0.09  
 (-0.07 , 0.25)  
Male 0.13  
 (-1.46 , 1.72)  
Non-Caucasian (ref = white) 0.52  
 (-0.46 , 1.50)  
Medicaid (ref = no) 1.68  
 (0.61 , 2.74)  
Household income (per $10,000) 0.12  
 (-0.13 , 0.36)  
Number of children 0.00  
 (-0.18 , 0.17)  
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Number of comorbidities -0.24  
 (-1.07 , 0.59)  
Caregiver live with person with 
dementia (ref = does not live with 
person) -0.53  
 (-1.86 , 0.80)  
Data for this model is from the Health and Retirement Study and Aging, 
Demographics and Memory Study subsample. Coefficients were used to predict 
hours of formal caregiving received in a month. Regression model used to 
predict time caregiving and out-of-pocket medical expenditures is published in 
Jutkowitz, E, et al. "Effects of cognition, function, and behavioral and 
psychological symptoms on out-of-pocket medical and nursing home 
expenditures and time spent caregiving for persons with dementia." Alzheimer’s 
& Dementia (2017). Regression model used to predict Medicare expenditures is 
published in Jutkowitz, E, et al. "Effects of cognition, function, and behavioral 
and psychological symptoms on Medicare expenditures and health care 
utilization for persons with dementia." The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences (2017).
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Table A6.9 Parameter values in best-case/worst-case sensitivity analysis 
Model Estimate1  Best-case  Worst-case 
Disease Progression   
Cognition, MMSE Parameters not varied in best-case/worst-case sensitivity 
analysis 
Function, number of functional limitations Parameters not varied in best-case/worst-case sensitivity 
analysis 
Behavioral and psychological symptoms, number of 
symptoms 
Parameters not varied in best-case/worst-case sensitivity 
analysis 
Transitions   
Probability of moving from community to long-term care 
facility 
Parameters not varied in best-case/worst-case sensitivity 
analysis 
Probability of moving from long-term care facility to 
community 
 
0 – 90 days 0.20 0.07 
90 – 180 days 0.0135 0.005 
180 – 365 days 0.0045 0.0015 
Probability of Medicare-Medicaid  
Community-dwelling 0.001 0.0031 
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Residing in long-term care facility 0.0095 0.0116 
Time Spent Caregiving and Expenditures  
Time receiving informal caregiving Parameters not varied in best-case/worst-case sensitivity 
analysis 
Medicare expenditures Parameters not varied in best-case/worst-case sensitivity 
analysis 
Out-of-pocket medical expenditures Parameters not varied in best-case/worst-case sensitivity 
analysis 
Time receiving formal caregiving Parameters not varied in best-case/worst-case sensitivity 
analysis 
Monthly private nursing home expenditures $5,089 $9,415 
Monthly Medicaid nursing home expenditures $4,365 $8,107 
1Due to the large number of parameters, for the sensitivity analysis we a-priori identified those parameters believed to 
have large impacts on the cost of care. For the parameters estimating the risk of transiting to Medicare-Medicaid the 
best/worst case value depends on the perspective of the payer. For example, a higher probability of transiting to Medicaid 
may represent a best-case scenario from an individual perspective. Conversely, from a Medicaid perspective this 
represents a worst-case scenario. In the sensitivity analysis we adopted a Medicaid perspective and assumed a higher 
probability of transition to Medicaid represented a worst-case scenario.
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Figure A6.10 Distribution of survival time 
Figure A6.10 Legend: Distribution of survival time for an average incident dementia case.  Length of the bar is equal to 
average life expectancy. 
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Figure A6.11 Annual total cost of dementia  
Figure A6.11 Legend: Discounted annual total cost of dementia for an 83-year-old incident case (base-case) by cost 
type. The value of informal caregiving is $21/hour.  Out-of-pocket expenditures include those for medical care, long-term 
care facility, and formal caregiving. Annual costs are calculated for those conditional on surviving the entire year. 
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Figure A6.12 Best-case/worst-case sensitivity analysis total and net cost of dementia 
Figure A6.12 Legend: Discounted total and net lifetime cost of dementia by cost type. Out-of-pocket expenditures include 
those for medical care, long-term care facility, and formal caregiving. The length of the bar is equal to average lifetime 
expenditures. Net cost represents the difference in expenditures between dementia cases and counterfactual dementia 
free cases.
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Table A6.13 Counterfactual analyses   
 
Value of informal 
caregiving 
Out-of-pocket 
expenditures 
Medicaid long-term 
care facility 
expenditures 
Medicare 
expenditures 
Total value 
of care 
Base-Case (83-year-old 
incident dementia case) 
$144,160 $88,800 $37,390 $52,540 $322,900 
Non-demented Counterfactuals1  
Counterfactual Dementia 
Free 
$2,620 $64,640 $28,090 $32,650 $128,000 
Counterfactual Dementia 
Free with 1 Functional 
Limitation 
$4,540 $68,860 $32,090 $38,360 $143,860 
Counterfactual Dementia 
Free with 3 Functional 
Limitations 
$12,850 $81,110 $36,780 $52,180 $182,920 
Counterfactual Dementia 
Free with 5 Functional 
Limitations 
$33,070 $98,260 $41,490 $70,980 $243,800 
Hypothetical Treatment Effect2 
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10% Reduction in 
Functional Decline 
$141,630 $88,020 $37,240 $51,980 $318,870 
10% Reduction in Number 
of Behavioral and 
Psychological Symptoms 
$143,740 $88,660 $37,280 52,490 $322,170 
Notes: The value of informal caregiving is $21/hour.  Out-of-pocket expenditures include those for medical care, long-term 
care facility, and formal caregiving. Costs of counterfactuals can be compared to the base-case to determine cost 
differences.  
1The counterfactual dementia free group was identical to the dementia group in terms of all demographic characteristics 
(e.g., age, gender, race), but the counterfactual did not experience cognitive deficits, functional limitations (unless 
otherwise noted), behavioral/psychological symptoms, an excess Medicaid transition risk, or excess mortality due to 
dementia.  
2Hypothetical treatment was assumed to reduce rate of functional decline by 10% or reduce the increase in 
behavioral/psychological symptoms by 10%.  Treatment was assumed to be implemented when MMSE≤21. Treatment 
effect was assumed to last for 12 months after which individuals experienced the same rate of decline as those in the 
base-case.    
